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SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is a chronic, irreversible, and life-threatening disease with a median 
survival of 3-5 years after diagnosis. The number of patients suffering from IPF is rapidly increasing, and 
therapeutic options are very limited. IPF is characterized by altered cellular composition and homeostasis 
in lung parenchyma, leading to excessive deposition of extracellular matrix (ECM), and ultimately, organ 
failure. Fibroblasts are the main cell types producing ECM in the lung. In general, fibroblasts play an 
important role in various cellular responses, including cell proliferation and migration, and therefore are 
essential for the processes of normal wound healing. The injury of the lung epithelium leads to the 
recruitment of inflammatory cells and the release of profibrotic growth factors, such as TGFβ, resulting in 
fibroblast to myofibroblast differentiation. Myofibroblasts represent a highly proliferating, migrating and 
increased ECM producing phenotype essentially participating in tissue remodeling of the fibrotic lung.  
Little information, however, exists regarding changes in the fibroblast surface proteome under growth factor 
stimulation, since the fibroblasts surface proteome is not well characterized to date. Therefore, we have 
initially performed a cell-surface proteome profiling of primary human lung fibroblasts (phLFs) and further 
analyzed the impact of TGFβ on it [Heinzelmann et al., 2016]. Here, we identified Platelet derived growth 
factor receptor-alpha (PDGFRα) and Cub domain containing protein 1 (CDCP1) among the top 
downregulated proteins. Thus, in my thesis I aimed to investigate in detail their functional role in lung 
fibroblasts and their impact on IPF. 
In the first part of this thesis, the effect of TGFβ on the total mRNA and protein expression as well as on 
cell surface localization of PDGFRα and CDCP1 in primary human lung fibroblasts (phLFs) was 
determined. We confirmed PDGFRα and CDCP1 surface localization and downregulation of expression 
levels by TGFβ. In the second part, functional roles of both surface proteins in phLFs were addressed. With 
a focus on PDGF signaling first, PDGF ligand-receptor interactions were analyzed showing that ligand 
PDGF-AB predominantly activates PDGFRα, whereas PDGF-DD activates PDGFRβ downstream signaling 
as demonstrated by increased Akt phosphorylation. Surprisingly, the expression of PDGFRβ receptor was 
increased in the absence of PDGFRα via siRNA-mediated knockdown. Moreover, the role of PDGF 
signaling in cell invasion was addressed showing that PDGF-AB-induced signaling increased invasion 
properties of human lung fibroblasts and this effect is mediated in a PDGFRα-dependent manner. 
Importantly, Nintedanib decreased TGFβ-increased αSMA and collagen V total protein expression, 
however, this effect was largely attenuated in PDGFRα-depleted cells. 
Analysis of CDCP1 regulation revealed that TGFβ downregulated CDCP1 expression in a time-dependent 
manner and this effect was potentially mediated via increased ubiquitin-independent proteasomal 
degradation of CDCP1, but not canonical or non-canonical TGFβ pathway. Interestingly, CDCP1 also 
affected downstream TGFβ signaling as demonstrated by increased Smad3 phosphorylation in CDCP1-
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depleted cells treated with TGFβ. Moreover, CDCP1 depletion enhanced TGFβ-mediated cell adhesion 
capacity of human lung fibroblasts. CDCP1 knockdown led to an increase in total protein expression levels 
of αSMA, collagen III, and collagen V in phLFs, which was independent of TGFβ. Importantly, αSMA-
positive interstitial myofibroblasts located in fibroblastic foci of IPF lung sections displayed a low 
expression of CDCP1, whereas non-differentiated interstitial lung fibroblasts in sections of donor lungs 
were highly CDCP1-positive, and clearly αSMA-negative.  
 
In sum, I showed in my study that TGFβ regulates the expression of fibroblasts surface proteins, as shown 
here for PDGFRα and CDCP1, which in turn modulates their function in lung fibroblasts and lung disease.  
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9 
 
1 INTRODUCTION 
 Idiopathic pulmonary fibrosis (IPF) 
Idiopathic pulmonary fibrosis (IPF) is defined as a chronic, progressive, and life-threatening lung disease 
with a median survival rate of 3-5 years from the time of diagnosis [Selman et al., 2001; Schwartz et al., 
1994; King et al., 2001a]. IPF belongs to the category of interstitial lung diseases (ILD), also named diffuse 
parenchymal lung diseases (DPLD), and is further classified within this category to the subgroup of 
idiopathic interstitial pneumonias (IIP) with histopathological features of usual interstitial pneumonia (UIP) 
[Visscher and Myers, 2006; American Thoracic Society and European Respiratory Society, 2002; Raghu et 
al., 2011]. Generally, the prevalence of IPF varies between 2 and 29 cases per 100.000 persons [Annesi-
Maesano et al., 2013]. Interestingly, the prevalence of IPF in the USA population is estimated between 42.7 
and 63 cases per 100.000 persons, whereas in Europe numbers vary between 1.25 and 23.4 cases per 100.000 
persons [Nalysnyk et al., 2012; Ley and Collard, 2013; Fernández Pérez et al., 2010].  
 
 Clinical presentation of IPF  
IPF is associated with the older population since most patients are between 60-70 years old at the time of 
diagnosis [Patterson et al., 2017]. There is no correlation between the ethnic group or social environment 
and IPF manifestation, however, IPF often affects men more than women, as indicated by its prevalence 
(20.2 men per 100.000 persons compared to 13.2 women per 100.000 persons) and the majority of patients 
have a smoking history [Annesi-Maesano et al., 2013]. The initial clinical symptoms of IPF are not well 
described to date; however, dry cough lasting at least for 8 weeks has been reported in IPF patients  [Hope-
Gill et al., 2003; Chung and Pavord, 2008; Ryerson et al., 2011]. Dry cough is particularly presented in 
patients who have never smoked or patients with an advanced stage of the disease [Nakamura and Suda, 
2015]. Moreover, dyspnea (shortness of breath) is another prominent symptom in IPF patients especially 
those in advanced stages of the disease [Swigris et al., 2005; King et al., 2001b]. Various studies have shown 
an evident correlation between the severity level of dyspnea and life quality/ survival rate in IPF patients 
[King et al., 2001b; Nishiyama et al., 2005]. Furthermore, clubbing fingers have been reported in 30-50 % 
of IPF patients, however their exact cause remains unknown [Nakamura and Suda, 2015]. IPF patients may 
also present clinical signs of weight loss, fatigue, or low-grade fever [Swigris et al., 2005; Atkins et al., 
2016]. 
 
 Diagnosis of IPF 
The natural origin of IPF has been described as a rapid decline in forced vital capacity (FVC, the maximal 
volume of gas exhaled from the full inhalation by exhaling as forcefully as possible) associated with poor 
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prognosis of IPF patients [Gross and Hunninghake, 2001; Tukiainen et al., 1983; Carrington et al., 1978]. 
For each patient, the origin of the disease is individual and unforeseeable at the time of diagnosis. Some 
patients display slow manifestation and progression, whereas others experience acute exacerbation 
relatively early from the time of diagnosis (Figure 1.1) [Mejía et al., 2009; Wells et al., 2003; Lettieri et al., 
2006; King et al., 2011]. 
 
 
 
Figure 1.1: Schematic illustration of potential clinical development and progression of IPF. The manifestation as well as 
progression of IPF is very individual for each patient. Majority of patients experience slow disease progression with stable 
worsening. Some patients experience acute worsening during this period, which mainly occurs because of secondary complications 
or due to unknown reasons. On the other hand, patients experience rapid disease progression relatively early from the time of 
diagnosis. Illustration was adapted and modified from King et al., 2011 [King et al., 2011].  
 
In general, IPF is hard to diagnose as it resembles symptoms similar to other pulmonary diseases. In order 
to avoid misdiagnosis, detailed medical history identifying possible environmental exposures, other 
extrapulmonary symptoms, and inherited disease predispositions must be considered [Martinez et al., 2017; 
Iwai et al., 1994; Hubbard et al., 1996; Miyake et al., 2005; Armanios et al., 2007; Tsakiri et al., 2007]. 
There are also several comorbid diseases, such as pulmonary hypertension, lung cancer and chronic 
obstructive pulmonary disease (COPD) associated with IPF, which also makes IPF diagnosis more difficult 
[Collard et al., 2012; Fernández Pérez et al., 2010; Mejía et al., 2009; Nadrous et al., 2005]. The diagnosis 
of IPF is most often determined by abnormal lung function confirmed via spirometry, or whole-body 
plethysmography (uncovering an evidence of restricted and/or impaired gas exchange) followed by high-
resolution computed tomography (HRCT) of the chest [Raghu et al., 2011; Behr et al., 2013]. If HRCT 
scans show a distinct pattern of usual interstitial pneumonia (UIP), IPF can be diagnosed. However, if UIP 
patterns remain inconclusive, surgical lung biopsy or bronchoscopy is recommended [Behr, 2013; Raghu et 
al., 2011]. A huge interest lies in identifying diagnostic biomarkers in body fluids. Although there are no 
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11 
 
validated biomarkers for predicting the prognosis and disease status of IPF yet, some potential candidates 
have been identified, such as MMP-7 and MUC5B [Bauer et al., 2017; Helling et al., 2017a; Hambly et al., 
2015; Guiot et al., 2017]. Furthermore, the role of circulating autoimmune antigens in IPF as indicators of 
IPF have been previously described [Dreisin et al., 1978]. In line with this, the protein MZB1 was recently 
identified in a proteome profiling of a large cohort of ILD and scleroderma tissue samples as an upregulated 
protein localizing to plasma B cells [Schiller et al., 2017]. Importantly, there is an increased interest in 
combining a comprehensive analysis of clinical and omics-generated data using bioinformatic approaches 
which will help to uncover novel biomarkers in ILDs [Greiffo et al., 2017].  
 
 Treatment strategies of IPF 
Treatment of IPF can be divided into non-pharmacological and pharmacological strategies. Regarding non-
pharmacological strategies, the 2011 ATS/ERS/JRS/ALAT committee guidlines approved long-term 
oxygen therapy, and lung transplantation [Raghu et al., 2011]. Lung transplantation is, to date, the only 
option to prolong and improve patiens' life quality. However there are only few patients who qualify for 
lung transplantation and the number of donor lungs is very low compared to the increased number of IPF 
patients [Glanville and Estenne, 2003].   
Over the last decade, pharmagological strategies focused on targeting various molecules and pathways 
playing a role in IPF. Specifically, targeting signaling pathways activated by receptor tyrosine kinases has 
been of high interest for several years as their abberant activity plays a central role in the manifestation and 
progression of fibrosis [Vittal et al., 2005; Garneau-Tsodikova and Thannickal, 2008; Beyer and Distler, 
2013]. The first clinical trial assessing the efficiency of tyrosine kinase inhibitors for treatment of lung 
fibrosis was completed in 2010; Imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeting platelet-
derived growth factor receptors (PDGFRs), discoidin domain receptors (DDRs), c-kit, and c-Abl [Daniels 
et al., 2010], however results showed no improvement of lung function and survival of IPF pantients enrolled 
in this study [Daniels et al., 2010]. 
Pirfenidone and Nintedanib have recently been approved by the European Medicines Agency (EMA, 
2011/2014) and the US Food and Drug Administration (FDA, 2015/2014) for the treatment of IPF patients, 
both showing a decrease in disease progression (Azuma et al. 2005; Elmufdi et al. 2015; Noble et al. 2011; 
Tzouvelekis, Bonella, and Spagnolo 2015). A one-year treatment of IPF patients with Pirfenidon slows 
decline in the force vital capacity (FVC) [Noble et al., 2016], but brings several adverse effects, such as 
gastrointestinal reflux or photosensitivity rush were reported [Valeyre et al., 2014]. The exact molecular 
mechanism of action is not well known, however it has been demonstrated that Pirfenidone downregulates 
TGFβ-mediated fibroblast proliferation, migration and synthesis of lung collagens [Noble et al., 2011; 
Hisatomi et al., 2012]. Nintedanib (BIBF1120) is a triple receptor tyrosine kinase inhibitor targeting platelet-
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derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and basic fibroblast growth 
factor (FGF) receptor described to be safe in use, and with diarrhea as the most common adverse effect 
known [Richeldi et al., 2014a]. Results from multinational double-blinded, phase III clinical trials 
(INPULSIS-1 and INPULSIS-2) reported decrease in the FVC; however, data were significant only in the 
INPULSIS-1 trial [Antoniu, 2012; Richeldi et al., 2014a; Rafii et al., 2013; Richeldi et al., 2014b]. Although 
positive results from above-mentioned clinical trials gives hope to IPF patients, the inhibition of tyrosine 
kinase receptors remains highly unspecific and affects several (un)known targets [Noskovičová et al., 2015]. 
There are still open questions regarding the use of Pirfenidone or Nintedanib in the clinics, such as 
unpredictable adverse effects and long-term perspective of the treatment. A deeper understanding of IPF 
pathogenesis will arise new opportunities to develop novel, and more effective and safe drugs for the 
treatment of IPF patients. 
 
 Histopathologic features of IPF  
According to the American Thoracic Society (ATS) consensus statement, IPF is associated with 
histopathological features of usual interstitial pneumonia (UIP) [Raghu et al., 2011]. The main 
histopathological features of UIP in surgical lung biopsies are described by heterogenous features due to 
irregularly distributed fibrotic scarring, honeycomb changes in a basal and subpleural area of the lung, and 
interstitial inflammation [American Thoracic Society and European Respiratory Society, 2002]. Tissue 
fibrosis prevails over inflammation and is accompanied with compact collagen deposition, often combined 
with smooth muscle cell hyperplasia [Raghu et al., 2011].  
The Fleischner society glossary described honeycombing as ''destroyed and fibrotic lung tissue which 
contains numerous cystic airspaces with thick fibrous walls, representing the late stage of various lung 
diseases, with complete loss of acinar architecture'' [Hansell et al., 2008]. Furthermore, accumulation of 
hyperproliferative fibroblasts and myofibroblasts characterized by expression of α-smooth muscle actin 
(αSMA) in regions called interstitial fibroblastic foci represent a key histological feature of UIP (Figure 1.2) 
[Katzenstein and Myers, 1998]. Fibroblast foci are considered as small, distinct lesions localized between 
alveolar and interstitial regions of the lung and their formation is linked with the sites of ongoing lung injury 
[King et al., 2001a; Nicholson et al., 2002; Flaherty et al., 2003]. Importantly, increased numbers of 
fibroblast foci have been associated with disease activity and a rapid disease progression [Enomoto et al., 
2006; Nicholson et al., 2002].  
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Figure 1.2: Histopathological features of UIP. Tissue stainings of α-smooth muscle actin (αSMA) in (A) a healthy donor lung 
and (B) UIP lung (brown, black arrowheads). Notice prominent αSMA stainings in myofibroblasts accumulated in fibroblastic foci 
of UIP lung (panel B, black arrowheads). Modified from Eickelberg and Laurent, 2010 [Eickelberg and Laurent, 2010]. 
 
 Pathogenesis of IPF  
According to the latest concept of IPF manifestation and progression, IPF is a disease resulting from 
impaired, non-resolving wound healing together with progressive accumulation of extracellular matrix 
(ECM) components, decreased fibroblasts-myofibroblasts apoptosis, persistent epithelial cell apoptosis and 
abnormal reepithelization [Daccord and Maher, 2016]. Inflammation is still considered as a main driver of 
IPF development as there is increasing evidence that inflammatory cells strongly contribute to the tissue 
injuries and repair [Coward et al., 2010]. 
The onset of IPF is thought to be the result of initial alveolar type I cells (ATI) injury leading to alveolar 
epithelial cells (AEC) apoptosis followed by disruption of the AEC layer [Sakai and Tager, 2013]. Recent 
findings suggest that persistent microinjuries to the lung epithelium may be triggered by a combination of 
environmental factors such as tobacco smoke, gastroesophageal reflux, and viruses together with genetic 
predisposition or age-related factors [Zoz et al., 2011; Selman and Pardo, 2006; Macneal and Schwartz, 
2012]. Regarding genetic predispositions, in the study of familial form of IPF, Nogee et al. identified a 
mutation in the gene encoding SPC (SFTPC) which led to fibrosis most likely due to the deficient expression 
and secretion of SPC protein, ER stress and cell apoptosis [Thomas et al., 2002; Mulugeta et al., 2007; 
Nogee et al., 2001]. Another study showed that mutations in age-related genes, such as telomerase reverse 
transcriptase (TERT) and telomerase RNA component (TERC) gene, may play a critical role in the 
development of IPF as observed in patients with familial and sporadic forms of IPF [Alder et al., 2008; 
Tsakiri et al., 2007; Cronkhite et al., 2008]. In general, telomeres shorten when cells divide, which finally 
leads to cell death or arrest of the cell cycle, thus resulting in the restricted capacity of tissue regeneration 
[Armanios, 2009]. This indicates a critical role of telomere shortening in age-related diseases. Additionally, 
it has been suggested that telomere shortening promotes the apoptosis of alveolar type II (ATII) cells, and 
thus promotes IPF manifestation [Alder et al., 2008; Waisberg et al., 2010]. MUC5B is a secreted mucin 
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with high expression levels in the normal respiratory tract, which is responsible for the clearance of upper 
airways from the potential bacterial infection preventing thus potential pathogen infiltration to the 
respiratory system [Roy et al., 2014]. An important study of Seibold and colleagues identified a single 
nucleotide polymorphism (SNP) located in the promoter region of the MUC5B gene (rs35705950) in 
patients with familial as well as sporadic IPF [Seibold et al., 2011]. Moreover, a recent study of Helling et 
al. identified a critical enhancer element in the promoter region of MUC5B gene which contains the 
rs35705950 variant of MUC5B gene [Helling et al., 2017b]. In addition, authors found that the enhancer 
element carries a highly conserved binding motif for transcription factor FOXA2, which may, together with 
RNA polymerase II, have an important role in regulating MUC5B transcription [Helling et al., 2017b]. The 
consequence of alteration in MUC5B gene increases the risk of developing IPF via chronic hypersecretion 
and accumulation of mucus in the peripheral airspace resulting in impaired mucus transport and its adhesion 
to bronchoalveolar space which promotes chronic inflammation and tissue injury [Seibold et al., 2011; 
Boucher, 2011]. Additionally, epigenetic modifications of genes associated with IPF, such as chemokine 
IP-10, Thy-1 (CD90), and ACTA (αSMA gene) were shown to play a role in the development of IPF [Coward 
et al., 2010; Sanders et al., 2008; Hu et al., 2010]. Sanders et al. showed in a comparative analysis of 
genome-wide DNA methylation combined with gene expression patterns from healthy and IPF lungs that 
expression of some IPF-related genes is inversely associated to DNA methylation of these genes [Sanders 
et al., 2012]. 
Due to the initial epithelial injury, it is next proposed that activated AECs start secreting increased amounts 
of profibrotic cytokines, chemokines, and proteases which subsequently leads to the recruitment and 
activation of inflammatory cells and fibroblasts to the site of injury [Todd et al., 2012]. In addition, the 
injury of AECs results in the activation of a coagulation cascade where fibrinogen is converted to fibrin to 
form a provisional matrix [Chambers and Scotton, 2012]. Here, chemokines and serum-derived mediators 
recruit fibroblasts, circulating cells and trigger epithelial-to-mesenchymal transition (EMT) of AECs. 
Subsequently, fibroblasts become activated by profibrotic cytokines, such as TGFβ and PDGF, which leads 
to their differentiation into highly contractile myofibroblasts, and which are thought to be the primary 
effector cells in IPF [Hinz et al., 2007a; Hinz, 2016]. Activated myofibroblasts produce and secrete 
excessive amounts of extracellular matrix (ECM) components and thus highly contribute to the progressive 
tissue remodeling and ultimately organ failure [Coward et al., 2010; White, 2015]. 
 
 Lung fibroblasts  
Fibroblasts are a cell population of mesenchymal origin representing the most abundant cell type of 
connective tissue [Kendall and Feghali-Bostwick, 2014]. Generally, fibroblasts can be phenotypically 
recognized by their typical spindle-shaped morphology [Ravikanth et al., 2011]. In the lung, fibroblasts are 
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found in proximal airways and also in distal lung parenchyma, but cells differ in their morphology and 
proliferation capacity dependent on the area of isolation, as described in lung biopsies from asthma patients 
[Kotaru et al., 2006].  
 
 Fibroblasts in wound healing 
Due to their high proliferative and migratory capacities [Suganuma et al., 1995; Moodley et al., 2003], 
fibroblasts play an essential role in wound healing processes [Li and Wang, 2011; Bainbridge P, 2013]. In 
the early stages of tissue injury, fibroblasts migrate towards the wound and subsequently differentiate into 
highly contractile myofibroblasts with increased production and secretion capacities of ECM proteins, such 
as elastin, collagens, and fibronectin [Thannickal et al., 2004; Martin, 1997]. Thus, they can build and 
maintain temporary scaffold necessary for normal tissue repair and wound closure. Once the wound is 
closed, provisional tissue scaffold dissolves and myofibroblasts disappear through apoptosis [Li and Wang, 
2011; Hinz et al., 2007a]. Although the exact mechanism of myofibroblasts apoptosis is not completely 
uncovered, this process is necessary for maintaining normal and healthy tissue architecture after injury 
[Desmoulière et al., 1995]. 
The main phenotypical differences between fibroblasts and myofibroblasts include large microfilaments, 
enlarged focal adhesions, abundant intracellular adherent molecules and gap junctions, increased ECM 
production and secretion and increased expression of alpha smooth muscle actin (αSMA), highly 
contributing to its contractile properties (Figure 1.3) [Kendall and Feghali-Bostwick, 2014; Hinz, 2007; 
Hinz et al., 2007a; Tomasek et al., 2002; Hinz et al., 2003; Dugina et al., 2001; Hinz et al., 2007b, 2001a; 
Serini et al., 1998]. Generally, the abundance of myofibroblasts in normal healthy lung is expected to be 
low, however their appearance become more prominent once wound healing processes are dysregulated as 
it is the case in IPF [Hinz, 2012].  
 
INTRODUCTION 
16 
 
 
 
Figure 1.3: Phenotypical differences between fibroblasts and myofibroblasts. Under normal conditions, resident fibroblasts 
(left images) maintain a classical spindle-shape morphology with hardly detectable expression of αSMA (A) and small, immature 
focal adhesions at cell edges (B, regular arrowheads). On the other hand, activated myofibroblasts (right images) display a highly 
contractile phenotype as shown by prominent αSMA expression (C) and super mature focal adhesions (D, bold arrowheads) 
(unpublished data). 
 
 Activated fibroblasts in IPF 
Fibroblasts and myofibroblasts in IPF exhibit a pathologic phenotype of uncontrolled proliferation, 
migration, and survival. Moreover, increased resistance to programmed cell death has been observed in 
primary human lung fibroblasts isolated from IPF tissues [White et al., 2003; Nho et al., 2013; Maher et al., 
2010]. In IPF, fibroblasts accumulate in fibroblastic foci (chapter 1.1.4), where they initially acquire 
contractile features by displaying stress fibers composed of cytoplasmic actin with very low traction forces 
[Hinz et al., 2001b]. Subsequently, changes in the ECM compositions as well as extracellular stimuli such 
as growth factors act on fibroblasts leading to their phenotypic changes into αSMA-expressing 
myofibroblasts. Incorporation of αSMA into stress fibers enlarges the contractile properties of fibroblasts, 
which is one of the hallmarks of initiated tissue remodeling [Hinz et al., 2001b]. Additionally, activated 
myofibroblasts are characterized by excessive production, secretion, and deposition of ECM components, 
such as collagens and fibronectin and thereby essentially contribute to fibrotic tissue remodeling [Klingberg 
et al., 2013]. 
Several studies, mostly by animal studies, have focused on identifying the origin and progenitors of 
myofibroblast. Resident fibroblasts, circulating bone-marrow derived fibrocytes, smooth muscle cells, 
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pericytes, epithelial and endothelial cells undergoing endothelial- or epithelial-mesenchymal transition, and 
mesenchymal stromal cells are discussed as potential sources (Figure 1.4) [Porter and Turner, 2009; Dranoff 
and Wells, 2010; De Wever et al., 2008; Hinz, 2007; Coen et al., 2011; Herzog and Bucala, 2010; Keeley 
et al., 2011; Humphreys et al., 2010; Lin et al., 2008; Lee and Nelson, 2012; Chapman, 2011; Mishra et al., 
2009].  
 
 
Figure 1.4: Myofibroblast precursor cells. In IPF, myofibroblasts can differentiate from various precursor cells including resident 
fibroblasts, pericytes, epithelial cells, endothelial cells, mesenchymal stromal cells, smooth muscle cells, and fibrocytes. Figure was 
adapted and modified from Fernandez and Eickelberg, 2012 [Fernandez and Eickelberg, 2012b]. 
 
 Molecular mechanisms regulating fibroblasts activation 
A large spectrum of profibrotic and antifibrotic factors act on fibroblasts by paracrine and autocrine 
mechanisms, driving fibroblast activation in fibrosis (Figure 1.5) (B Hinz et al., 2001b; Kendall & Feghali-
Bostwick, 2014; Tomasek et al., 2002; White, 2015; Wolters, Collard, & Jones, 2014). Transforming growth 
factor-beta (TGFβ) and platelet-derived growth factor (PDGF) are the most intensively studied profibrotic 
pathways regulating fibroblast to myofibroblast transdifferentiation in IPF [Scotton and Chambers, 2007; 
Khalil et al., 1993a; Allen and Spiteri, 2002]. Also, members of Wnt/β-catenin pathway were recently 
reported to prompt profibrotic responses from epithelial cells toward fibroblasts in IPF [Königshoff et al., 
2009]. On the other hand, prostaglandin E2 (PGE2) and prostacyclin (PGI2) pathways were shown to 
mediate anti-fibrotic signals from epithelial cells towards fibroblasts by inhibiting proliferation, collagen 
production, and myofibroblasts differentiation in lung fibroblasts [Goldstein and Polgar, 1982; Kolodsick 
et al., 2003; McAnulty et al., 1997].  
 
INTRODUCTION 
18 
 
 
 
Figure 1.5: A schematic overview of profibrotic stimuli promoting myofibroblasts transdifferentiation in IPF. Various 
profibrotic factors act on fibroblasts leading to their transdifferentiation into myofibroblasts. Activated myofibroblasts also release 
several profibrotic cytokines by which they contribute to inflammation and ongoing fibrosis. Autocrine factors produced by 
fibroblasts act on fibroblasts and thus promote their profibrotic phenotype. Figure was adapted and modified from Kendall and 
Feghali-Bostwick, 2014 [Kendall and Feghali-Bostwick, 2014]. 
 
 Transforming growth factor-beta (TGFβ) signaling  
TGFβ is one of the most extensively studied profibrotic growth factors which plays a crucial role in the 
development and progression of IPF [Fernandez and Eickelberg, 2012a; Kendall and Feghali-Bostwick, 
2014; Klingberg et al., 2013]. TGFβ signaling promotes chemotaxis and proliferation of fibroblasts, EMT 
and protects myofibroblasts from apoptosis in IPF [Maher and Adamali, 2012]. In the lung, alveolar 
macrophages, neutrophils, activated alveolar epithelial cells, endothelial cells, fibroblasts, and 
myofibroblasts are the main sources of TGFβ secretion [Merrilees and Sodek; Kumar et al., 1996; 
Grotendorst et al., 1989; Khalil et al., 1993b; Kelley et al., 1991]. To date, there have been three different 
TGFβ isoforms described - TGFβ1, TGFβ2, and TGFβ3, of which only TGFβ1 is found to be upregulated 
in IPF [Khalil et al., 1996; Yong et al., 2001]. TGFβ ligands are synthesized as latent precursors forming a 
complex with their latency-associated peptide (LAP), and a latent TGFβ-binding protein (LTBP), together 
creating a large latent complex (LLC). The activation of latent TGFβ requires the liberation of LLC complex 
from the ECM followed by further proteolytical cleavage of LAP [Hinz, 2015]. Several extracellular factors, 
such as integrins, matrix metalloproteinase 2 and 9 (MMP2 and MMP9) and thrombospondin 1 (THBS1) 
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have been described to activate latent TGFβ [Annes et al., 2003; Henderson et al., 2013; Schultz-Cherry et 
al., 1994]. 
Once activated, TGFβ signals via binding to two heterodimeric receptors, namely TGFβ type I (TGFβRI) 
and type II (TGFβRII) belonging to the family of serine/threonine kinase receptors [Itoh et al., 2000; 
Derynck and Feng, 1997; Moustakas et al., 2001]. First, TGFβ binds to the extracellular domain of TGFβRII 
which in turn recruits TGFβRI resulting in dimerization of both receptors forming a heterodimeric receptor 
complex, leading to phosphorylation and subsequent activation of the TGFβRI-mediated intracellular 
signaling cascade [Feng and Derynck, 1996]. Downstream TGFβ signaling is mediated via two signaling 
pathways: Smad-dependent (canonical) pathway and Smad-independent (non-canonical) pathway [Derynck 
and Zhang, 2003].  
 
1.2.4.1 Smad-dependent signaling  
In the Smad-dependent signaling pathway (Figure 1.6), activation of TGFβRI leads to the phosphorylation 
of cytoplasmic signaling molecules Smad2 and Smad3 known also as receptor-specific (R-Smad) proteins 
[Itoh et al., 2000]. R-Smads couple with coregulator Smad4 which leads to the translocation of Smad2/3-
Smad4 complex into the cell nucleus where they act as transcription factors binding either directly or in a 
complex with other DNA-binding proteins to the promotor region of TGFβ-signaling target genes [Shi and 
Massagué, 2003]. Interestingly, Smad3 can directly bind to CAGAC DNA sequence as observed by several 
groups, whereas Smad2 requires DNA-binding protein from the Fast family to bind DNA [Shi et al., 1998; 
Zawel et al., 1998; Attisano et al., 2001]. In addition, inhibitory Smads (I-Smads), such as Smad6 and Smad7 
regulate balanced phosphorylation and nuclear translocation of R-Smad/Smad4 complex into the nucleus 
[Kawabata et al., 1997; Nakao et al., 1997]. It has been shown that under normal conditions, Smad signaling 
regulates expression of ECM-related genes, such as Col1A1, Col3A1, and Col5A1 [Verrecchia et al., 2001]. 
In IPF, aberrantly activated Smad signaling results in increased expression levels of collagens and also other 
ECM proteins, such as fibronectin, elastin, and integrins by fibroblasts [Pechkovsky et al., 2012; Kuang et 
al., 2007; Ignotz and Massagué, 1986; Honda et al., 2010]. Additionally, transcription of ACTA2 (encoding 
for αSMA) is regulated by canonical Smad2/3 signaling via binding of Smad3 to the Smad-binding element 
1 at the αSMA promoter [Hu et al., 2003; Uemura et al., 2005].  
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Figure 1.6: A schematic illustration of Smad-dependent signaling pathway. Smad-dependent signal transduction is initiated by 
binding of TGFβ ligand to TGFβRII receptor, which results in the phosphorylation, and thus activation of TGFβRI receptor. 
Activated TGFβRI receptor then phosphorylates downstream signaling molecules Smad2 and Smad3 (R-Smads), which form 
complexes with the coregulator Smad4. Finally, Smad2/3-Smad4 complexes are translocated into the nucleus, where they act as 
transcription factors of TGFβ-related genes. The scheme is adapted from Jiang et al. [Jiang et al., 2015]. 
 
1.2.4.2 Smad-independent signaling 
Although TGFβ mostly signals via Smad pathway, activation of TGFβRI also promotes signal transduction 
via Smad-independent pathways (Figure 1.7). These different downstream pathways include Erk-mediated 
non-Smad pathway, JNK/p38 pathway, PI3K/Akt pathway, and the small Rho-like GTPase pathway [Shi-
Wen et al., 2009; Mucsi et al., 1996; Frey and Mulder, 1997; Engel et al., 1999; Hocevar et al., 1999; 
Derynck and Zhang, 2003; Sandbo et al., 2011]. Activation of these pathways leads to changes in the cell 
shape and regulation of gene programs that mediate fibroblasts differentiation and survival [Sandbo and 
Dulin, 2011; Horowitz et al., 2004]. Of interest, TGFβ receptors belong to the family of serine/threonine 
kinases; however, they can also undergo phosphorylation on their tyrosine residues [Lawler et al., 1997]. 
Thus, upon TGFβ ligand binding, both TGFβ receptors as well as signaling adaptor protein Shc become 
phosphorylated which in turn recruits adaptor proteins Grb2 and Sos to bind, resulting in activation of 
downstream MAPK kinase cascade via Raf, Mek, and Erk. Activated MAPK-Erk pathway further regulates 
disassembly of cell adherent junctions resulting in the increased migration and invasion of cancer cells 
during processes of TGFβ-induced EMT [Ravichandran, 2001; Davies et al., 2005]. Additionally, it has 
been reported that Erk substrates, such as AP-1 transcription factor can interact and function in the 
combination with Smads as regulators of transcription of various genes, such as Timp-1 and MMP-1 [Hall 
et al., 2003]. JNK/p38 pathway is one of the best characterized non-Smad signaling pathway. It is initiated 
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by binding of adaptor protein TRAF6 to intracellular domains of activated TGFβ receptors, subsequently 
resulting in K63-linked polyubiquitination of TRAF6. Unlike K48-linked polyubiquitination by which 
proteins are subjected for a proteasomal degradation [Grice and Nathan, 2016], K63-linked 
polyubiquitination mediates activation of protein substrates [Haglund and Dikic, 2005]. Thus, activated 
TRAF6 recruits, and further phosphorylates TAK1 by which downstream JNK/p38 pathway becomes 
activated [Wang et al., 2001]. Of note, TRAF6-TAK1-JNK/p38 pathway also regulates TGFβ-mediated 
cellular responses such as apoptosis and EMT via interaction between JNK/p38 and Smads in the cell 
nucleus [Yamashita et al., 2008]. 
 
 
 
Figure 1.7: A schematic illustration of Smad-independent signaling pathway. It is well established that TGFβ also activates 
multiple Smad-independent pathways through either phosphorylation or direct interaction of TGFβ receptors with non-Smad signal 
transducers. This includes signaling molecules of various branches of MAP kinase (MAPK) pathway, Rho-like GTPase signaling 
pathway, and phosphatidylinositol-3-kinase (PI3K)/ AKT pathway. The scheme is adapted from Wharton and Derynck [Wharton 
and Derynck, 2009]. 
 
 Fibroblasts surface proteins 
Fibroblasts, as any other cell type, gets in contact within the organ microenvironment via its surface 
molecules. This includes physical interaction with the ECM or cell-cell communication by cytokine-
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receptor interaction, further mediating and affecting its cellular function [Rozario and DeSimone, 2010]. 
The few studies existing characterized surface proteome of fibroblasts [Slany et al., 2014; Predic et al., 
2002]. However, identification of specific fibroblast surface markers remains challenging as fibroblasts, 
myofibroblasts, and other contractile cell types such as smooth muscle cells (SMCs) showed similar 
expression patterns of surface proteins [Hinz, 2007].  
In IPF, binding of several growth factors to fibroblast receptors and their functional consequences have 
mainly been described, as e.g. for TGFβ signaling and the phenotypic switch towards the highly proliferating 
and migratory myofibroblast [Fernandez and Eickelberg; Sakai and Tager, 2013]. Little information, 
however, exists how cytokines alter expression and localization of surface proteins, and thereby changing 
the binding and further interaction capacities of the cell.  
In a recently published comprehensive study investigating changes of the fibroblasts surface proteome after 
TGFβ stimulation, we identified platelet-derived growth factor receptor-alpha (PDGFRα) and Cub domain-
containing protein 1 (CDCP1) as one of the top candidates regulated by TGFβ [Heinzelmann et al., 2016]. 
These two proteins have been the focus of my thesis and will be introduced in more detail in the following.  
 
 Platelet-derived growth factor receptor-alpha (PDGFRα)  
Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) represent a family of profibrotic 
growth factors intensively studied in the lung field since aberrant PDGF signaling has been implicated in 
IPF pathogenesis [Vaillant et al., 1996; Bonner, 2004b; Kelly et al., 2003]. In general, PDGF signaling plays 
an important role in processes of normal wound healing by regulating migration and ECM deposition of 
fibroblasts [Alvarez et al., 2006]. However, during fibrogenesis, injured epithelial cells and recruited 
macrophages secrete excessive amounts of PDGF ligands which contribute to the impaired biological 
responses of activated myofibroblasts, such as resistance to apoptosis, and excessive proliferation, and 
migration to the site of the injury [Bonner, 2004b].  
To date, five heterodimeric PDGF ligand isoforms have been described; namely PDGF-AA, PDGF-AB, 
PDGF-BB, PDGF-CC and PDGF–DD [Li et al., 2000; Boström et al., 2002; Kimani et al., 2009]. Those 
ligands showed distinct binding affinities towards three PDGF receptor dimers – PDGFRαα, PDGFRαβ, 
and PDGFRββ (Figure 1.8). According to in vitro studies PDGF-AA, PDGF-AB, PDGF-BB, and PDGF-
CC bind PDGFRα, whereas PDGF-BB and PDGF-DD to PDGFRβ [Noskovičová et al., 2015]. On the other 
hand, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD display binding affinities toward heterodimeric 
PDGFRαβ [Gilbertson et al., 2001; Cao et al., 2002; LaRochelle et al., 2001].  
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Figure 1.8: A schematic overview of PDGF receptors and PDGF/PDGFR binding patterns. PDGFRs are transmembrane 
tyrosine kinase receptors spanning the cell surface of most cell types. Three dimeric receptor forms exist, namely homodimeric 
PDGFRαα and PDGFRββ, and one heterodimeric PDGFαβ receptor. Five different PDGF ligand isoforms possess specific binding 
affinities towards those receptors as indicated. The black solid arrows display in vitro documented binding interactions whereas 
dotted arrows show potential binding affinities. Adapted from [Noskovičová et al., 2015]. 
 
PDGFRα and PDGFβ belong to the family of receptor tyrosine kinases (RTKs) [Claesson-Welsh et al., 
1989; Matsui et al., 1989]. Inactive PDGFRs are first presented as monomeric receptor units on the cell 
surface. Once PDGF ligands bind to its respective receptors, conformational changes within the receptors 
occur which leads to receptor dimerization and thus autophosphorylation of the tyrosine residues in their 
intracellular domain [Noskovičová et al., 2015]. This leads to further downstream signaling via two main 
pathways: the phosphatidylinositol 3’-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) 
pathway and the MAPK cascade signaling pathway.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
In PI3K/Akt/mTOR pathway, activated PDGF receptor first recruits PI3K which is accompanied by 
phosphorylation of PIP2 into PIP3. This activates phosphoinositide-dependent kinase-1 which in turn 
activates Akt. Activated Akt stimulates signal transduction of various signaling molecules including mTOR 
controlling cellular growth, proliferation, and cell survival [Noskovičová et al., 2015]. On the other hand, 
MAPK dependent signaling pathway is initiated by phosphorylation of Shc protein and adaptor growth 
factor receptor-bound protein 2 (Grb2) which directly bind to autophosphorylated PDGF receptors via their 
SH2 domains. Subsequently, the SH3 domain of Grb2 couples with SOS, a nucleotide exchange factor of 
Ras leading to hydrolytic conversion of RAS-guanosine diphosphate (RAS-GDP) to RAS-guanosine 
triphosphate (GTP). Activated Ras then transduces the signal by Raf-1 and MAPK cascade members MEK 
and ERK. Thus this pathway takes part in specific cell responses such as cell growth, proliferation, 
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differentiation and migration [Noskovičová et al., 2015]. Moreover, several studies have reported crosstalk 
between PDGF-and other signaling pathways such as EGFR, leading to PDGF-B-stimulated cell migration 
of mouse embryonic cells [Mendelson et al., 2010].  
Aberrant PDGF signaling plays a critical role in IPF pathogenesis, that is why research in the past has 
focused on targeting PDGF signaling in the lung by inhibiting PDGF ligands, receptors or PDGF receptor-
kinase activity [Noskovičová et al., 2015].  
 
 Cub domain containing protein 1 
Cub domain containing protein 1 (CDCP1) is a cell surface glycoprotein which is also known as Subtractive 
Immunization Associated 135 kDa (SIMA135), gp40, or Transmembrane and associated with Src kinases 
(Trask) [Brown et al., 2004a; Hooper et al., 2003; Bhatt et al., 2005]. The expression of CDCP1 has been 
described in various cell types, including lung epithelial cells, hepatocytes, and hematopoietic progenitor 
cells and different organs such as breast, kidney, and colon [Hooper et al., 2003; Bühring et al., 2004; Siva 
et al., 2008; Emerling et al., 2013; Wright et al., 2016; Scherl-Mostageer et al., 2001].  
Aberrant CDCP1 expression has been associated with development and progression of various cancers 
including lung, breast, and colon cancer [Bühring et al., 2004; Scherl-Mostageer et al., 2001], as e.g. 
elevated expression levels of CDCP1 significantly contribute lung adenocarcinoma, and therefore represent 
a potential therapeutic target for cancer treatment [Chiu et al., 2015; Wortmann et al., 2009]. It has been 
shown that phosphorylated CDCP1 interacts with specific molecules such as Src, Yes, Fyn, and PKCδ, and 
thus promotes resistance to apoptosis by increased invasion and metastatic properties of cancer cells [Uekita 
et al., 2007, 2008b; Bhatt et al., 2005]. Additionally, activated CDCP1 couples with β1 integrin subunit, 
which in turn induces intracellular FAK/PI3K-mediated Akt signaling pathway, by which cancer cells gain 
their migratory properties [Casar et al., 2014]. Interestingly, some studies suggested that CDCP1 may also 
act as a marker of leukemia, since normal peripheral blood cells lack CDCP1 [Bühring et al., 2004]. 
Dysregulated expression of CDCP1 in various cancers might be the result of epigenetic modifications. In 
breast cancer samples Ikeda and colleagues demonstrated an opposite correlation between mRNA levels 
and methylation status of CpG motifs in the transcription initiation site of the CDCP1 gene [Perry et al., 
2007; Ikeda et al., 2009]. Consistently, inverse correlation between CDCP1 mRNA levels and CpG 
methylation was found in hematopoietic cell lines [Kimura et al., 2006]. To our knowledge, no information 
exists about CDCP1 expression in fibroblasts or its role in IPF. 
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2 OBJECTIVES 
Little information exists about the lung fibroblast surface proteome in general as well as its changes under 
normal and growth factor stimulation since specific fibroblasts surface markers have not been identified to 
date. The working group of Prof. Eickelberg therefore performed an unbiased proteome analysis of primary 
human lung fibroblasts in the presence/absence of TGFβ. By this, they wanted to determine markers 
significantly enriched on the cell surface, and identify proteins potentially regulated by TGFβ signaling and 
thereby contributing to the profibrotic phenotype. The surface fraction of fibroblasts was analyzed by mass 
spectrometry in collaboration with Dr. Stefanie Hauck and Dr. Juliane Merl-Pham (Research Unit Protein 
Science, Helmholtz Zentrum München) [Heinzelmann et al., 2016]. They identified 750 proteins by a 2-
peptide hit, among which 213 surface proteins were significantly regulated by TGFβ, thereof 70 proteins 
up- and 143 downregulated. These proteins were ranked by their fold change values and among the 15 top 
up and down regulated surface proteins by TGFβ markers randomly chosen for data validation. Down- and 
upregulation of ROR1, PDGFRα and SEMA7A by TGFβ, respectively, was confirmed via immunoblot and 
additionally FACS analysis for PDGFRα.  
In the first part of my project we continued working on PDGFRα, whereas in parallel I performed an 
intensive literature research to identify novel candidates to be regulated by but not associated yet with TGFβ 
or fibrosis. This lead to the detailed characterization of CDCP1 in the second part of this work in hand. 
 
I first aimed to confirm the effect of TGFβ on the expression of PDGFRα and CDCP1 in detail by analyzing 
RNA and protein levels and visualizing the effect on proteins’ surface localization. CDCP1 expression and 
function has only been little characterized in general and mainly in epithelial cells. PDGFRα and PDGF 
signaling on the other hand, have been associated with pulmonary fibrosis [Abdollahi et al., 2005]. But the 
precise mechanisms of PDGF signaling in the context of TGFβ in human lung fibroblasts had not been 
clarified when I started this project.  
Thus, the second aim of this thesis was to examine PDGF signaling in dependency of PDGFRα expression 
in human lung fibroblasts, as well as the impact of TGFβ on it, and to describe for the very first time 
functional properties of transmembrane glycoprotein CDCP1 in lung fibroblasts under basal conditions and 
TGFβ stimulation. I thereby aimed to investigate whether a potential cross-talk between PDGFRα and TGFβ 
pathway exists and whether this contributes to fibroblast differentiation to a profibrotic phenotype. 
Furthermore, I aimed to investigate whether activated and non-activated cells express CDCP1, and how 
does TGFβ regulate CDCP1 expression in lung fibroblasts. Finally, I aimed to uncover whether the presence 
or absence of both, PDGFRα and CDCP1, modify functional role of activated fibroblasts as main producers 
of ECM components in lung fibrosis.      
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3 MATERIALS AND METHODS 
 
       Materials 
 Chemicals and reagents  
Table 3.1: Chemical and reagents 
Product Company 
0.25% Trypsin-EDTA solution  Sigma-Aldrich; Taufkirchen, Germany 
2-Phospho-L-ascorbic acid trisodium salt Sigma-Aldrich; Taufkirchen, Germany 
87% Glycerol AppliChem; Darmstadt, Germany 
Ammonium peroxodisulfate (APS) AppliChem; Darmstadt, Germany 
Antibody diluent Zytomed Systems; Berlin, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich; Taufkirchen, Germany 
Bright-Glo™ Luciferase Assay System Promega, Mannheim, Germany 
Complete® Mini without EDTA (Protease-inhibitor) Roche Diagnostics; Mannheim, Germany 
Collagen G from bovine calf skin Merck Millipore; Berlin, Germany 
DAPI (4', 6-diamino-2-phenylindole) Sigma-Aldrich; Taufkirchen, Germany 
Desoxyribonucleotides mix (dNTPs)  Fermentas, Thermo Fisher Scientific; Schwerte, 
Germany 
Dimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem; Darmstadt, Germany 
ECL Plus Western Blotting Substrate Pierce, Thermo Fisher Scientific; ; Schwerte, 
Germany 
Ethanol (p.a.) AppliChem; Darmstadt, Germany 
Fetal bovine serum (FBS) ''GOLD '', heat inactivated PAA, GE Healthcare; Freiburg, Germany 
Fluorescence mounting medium Dako; Hamburg, Germany 
Glo Lysis Buffer, 1x Promega, Mannheim, Germany 
Human TruStain FcXTM BioLegend; San Diego, USA 
Isopropanol (p.a.)  AppliChem; Darmstadt, Germany 
Light Cycler 480 SybrGreen 1 Master Mix Roche Diagnostics; Mannheim, Germany 
Lipofectamine LTX with PLUS reagent Invitrogen, Life Technologies; Carlsbad, USA 
Lipofectamine RNAiMAX Invitrogen, Life Technologies; Carlsbad, USA 
Methanol (p.a.) AppliChem; Darmstadt, Germany 
Non-fat dried milk powder AppliChem; Darmstadt, Germany 
Nonidet P-40 AppliChem; Darmstadt, Germany 
Paraformaldehyde (PFA) AppliChem; Darmstadt, Germany 
Penicillin-Streptomycin (100 U/ml) Gibco, Life Technologies; Carlsbad, USA 
Phalloidin Invitrogen, Life Technologies; Carlsbad, USA 
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PhospSTOP (Phosphatase-inhibitor) Roche Diagnostics; Mannheim, Germany 
Protein marker V Peqlab; Erlangen, Germany 
Random hexamers Applied Biosystems, Life Technologies; Carlsbad, 
USA 
Recombinant human PDGF-AA protein Invitrogen, Life Technologies; Carlsbad, USA 
Recombinant human PDGF-AB protein Invitrogen, Life Technologies; Carlsbad, USA 
Recombinant human PDGF-CC protein R&D Systems; Minneapolis, USA 
Recombinant human PDGF-DD protein R&D Systems; Minneapolis, USA 
Recombinant human TGFβ1 protein R&D Systems; Minneapolis, USA 
Restore Plus Western Blot Stripping Buffer 
Pierce, Thermo Fisher Scientific; Schwerte, 
Germany 
Sircol, Alkali Reagent Biocolor; Northern Ireland, U.K. 
Sircol, Acid Neutralizing Reagent Biocolor; Northern Ireland, U.K. 
Sircol, Acid-Salt Wash Reagent (Concentrate) Biocolor; Northern Ireland, U.K. 
Sircol, Collagen Isolation & Concentration Reagent Biocolor; Northern Ireland, U.K. 
Sircol, Dye Reagent Biocolor; Northern Ireland, U.K. 
Sircol, Bovine Collagen Reference Standard  Biocolor; Northern Ireland, U.K. 
SuperSignal West Dura Chemiluminescent Duration Substrate Pierce, Thermo Fisher Scientific; Schwerte, 
Germany 
SuperSignal West Femto Chemiluminescent Duration Substrate Pierce, Thermo Fisher Scientific; Schwerte, 
Germany 
TEMED AppliChem; Darmstadt, Germany 
Tween 20 AppliChem; Darmstadt, Germany 
Tryptan Blue Solution (0.4%) Sigma-Aldrich; Taufkirchen, Germany 
UltraPure DNase/RNase-Free Distilled Water Invitrogen, Life Technologies; Carlsbad, USA 
Vybrant® CFDA SE intracellular dye  ThermoFisher Scientific; Rockford, USA 
 
 Consumables 
Table 3.2: Consumables 
Product Company 
µ-Plate 24 Well Ibidi; Planegg/Martinsried, Germany 
96-well imaging plates, Falcon® Corning, Thermo Fisher Scientific; Schwerte, 
Germany 
white 96-well microplates  Berthold Technologies; Bad Wildbad, Germany 
Amicon Ultra 3K-0.5 mL centrifugal filters Merck Millipore; Darmstadt, Germany 
Cell culture dishes Corning, Thermo Fisher Scientific; Schwerte, 
Germany 
Cell culture multi-well plates TPP Techno Plastic Producers; Trasadingen, 
Switzerland 
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Cell scrapers Corning, Thermo Fisher Scientific; Schwerte, 
Germany,  
Cotton Swabs, PP applicator 150 x 2.5 mm, for Sircol assay Laboratory Analysis LTD; Topsham, UK 
Combitips advanced® Eppendorf ; Hamburg, Germany 
Cryovials 1.5 ml Greiner Bio- One; Frickenhausen, Germany 
FACS tubes BD Bioscience; Heidelberg, Germany 
Falcon Tube (15 ml, 50 ml) BD Bioscience; Heidelberg, Germany 
Filter Tips Biozym Scientific; Hessisch Oldendorf, Germany 
Glas Pasteur pipettes VWR International; Darmstadt, Germany 
Hyperfilm ECL Film Amersham, GE Healthcare; Freiburg, Germany 
Protein LoBind Tubes (1.5 ml) Eppendorf; Hamburg, Germany 
Measuring pipettes, sterile, single use (5 ml, 10 ml, 25 ml, 50 ml) VWR International; Darmstadt, Germany 
Microscope slides Thermo Fisher Scientific; Darmstadt, Germany 
Nylon filters, pore size 70 µm BD Bioscience; Heidelberg, Germany 
PCR plates, 96-well plate Kisker Biotech; Steinfurt, Germany 
PVDF membrane Merck Millipore; Darmstadt, Germany 
Reaction tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf; Hamburg, Germany 
Reagent reservoirs, 50 mL Corning; New York, USA 
Sealing foils for PCR plates Kisker Biotech; Steinfurt, Germany 
Tips  Eppendorf; Hamburg, Germany 
Whatman blotting paper, 3 mm GE Healthcare; Freiburg, Germany 
 
 Cell culture media 
Table 3.3: Media 
Type Company 
DMEM/F12 (1:1) Gibco, Life Technologies; Carlsbad, USA 
Opti-MEM I Reduced Serum Medium Gibco, Life Technologies; Carlsbad, USA  
 
 Small interfering RNA (siRNA) 
Table 3.4: Human siRNAs 
siRNA Company Product number 
scrambled Silencer® Negative control No. 1 Ambion, Life Technologies; Carlsbad, USA AM4611 
Silencer® Select PDGFRα siRNA Ambion, Life Technologies; Carlsbad, USA s10235 
Silencer® Select PDGFRβ siRNA Ambion, Life Technologies; Carlsbad, USA s10240 
Silencer® Select CDCP1 siRNA Ambion, Life Technologies; Carlsbad, USA s35060 
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 DNA constructs 
Table 3.5: DNA plasmids 
Type Company 
pGL4-10, control vector Promega; Mannhein, Germany 
pGL3-CAGA(9)-luc [Dennler et al., 1998] 
 
 Inhibitors and antagonists 
Table 3.6: Inhibitors and antagonists 
Product Function Stock 
concentration 
Working 
concentration 
Solvent Company 
Nintedanib 
(BIBF 1120) 
Inhibitor of VEGF1/2/3, 
FGFR1/2/3, PDGFR 
1 mM 1 µM DMSO Selleckchem; 
Munich, Germany 
Imatinib Mesylate 
(STI571) 
Inhibitor of v-Abl, c-Kit and 
PDGFR 
10 mM - DMSO Selleckchem; 
Munich, Germany 
SB431542 Inhibitor of ALK5 receptor 10 mM 10 µM DMSO Tocris Bioscience; 
Bristol, U.K. 
Sis3 Inhibitor of pSmad3 3 mM 6 µM DMSO Tocris Bioscience; 
Bristol, U.K. 
UO126 Inhibitor of pErk 10 mM 10 µM DMSO Tocris Bioscience; 
Bristol, U.K. 
SCH79797 Inhibitor of PAR1 10 mM 0.05 – 1 µM DMSO Tocris Bioscience; 
Bristol, U.K. 
FSLLRY-NH2 Peptide antagonist of PAR2 10 mM 0.1 – 10 µM MilliQ 
H2O 
Tocris Bioscience; 
Bristol, U.K. 
GM6001 
(Ilomastat, Galardin) 
Broad spectrum MMPs 
inhibitor (MMP1-3, MMP7-9, 
MMP12, MMP14, and 
MMP26) 
5 mM 0.1 – 10 µM DMSO Selleckchem; 
Munich, Germany 
Bortezomib Inhibitor of proteasome 2.6 mM 1 – 10 nM PBS Milleium, Takeda; 
MA, USA 
Bafilomycin A1 Inhibitor of the late phase of 
autophagy 
10 µM 1 – 10 nM DMSO Sigma-Aldrich; 
Taufkirchen, 
Germany 
 
 Antibodies 
Table 3.7: Primary antibodies for Western blot 
Antibody Host Dilution Molecular 
size 
Company 
PDGFRα 
(sc-338) 
rabbit 1:500 170 kDa Santa Cruz Biotechnology; Dallas, 
USA 
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PDGFRβ 
(sc-432) 
rabbit 1:500 170 kDa Santa Cruz Biotechnology; Dallas, 
USA  
Akt 
(9272S) 
rabbit 1:1000 60 kDa Cell Signaling; Danvers, USA 
Phospho-Akt (Ser473) (D9E) XP 
(4060S) 
rabbit 1:1000 60 kDa Cell Signaling; Danvers, USA 
Anti - Smad3 
(ab28379) 
rabbit 1:1000 58 kDa Abcam; Cambridge, UK 
Phospho anti - Smad3 (S423+S425) 
(ab52903) 
rabbit 1:1000 58 kDa Abcam; Cambridge, UK  
Collagen type I 
(600-401-103-0.5) 
rabbit 1:5000 230 kDa Rockland; Gilbertsville, USA 
Collagen type III 
(600-401-105-0.1) 
rabbit 1:5000 250 kDa Rockland; Gilbertsville, USA 
Collagen type V (Col5A1) 
(sc-20648) 
rabbit 1:1000 260 kDa Santa Cruz Biotechnology; Dallas, 
USA 
Fibronectin 
(sc-9068) 
rabbit 1:500 220 kDa Santa Cruz Biotechnology; Dallas, 
USA 
anti-actin, α-smooth muscle (αSMA)  
(A5228) 
mouse 1:1000 42 kDa Sigma; St. Louis, USA  
CDCP1 
(4115) 
rabbit 1:1000 135 kDa Cell Signaling; Danvers, USA 
Erk1/2 (phospho44/42) 
(9101) 
rabbit 1:1000 44, 42 kDa Cell Signaling; Danvers, USA 
Anti-Erk1 
(554100) 
mouse 1:1000 44 kDa BD; Franklin Lakes, USA 
Anti-Erk2 
(610103) 
rabbit 1:1000 42 kDa BD; Franklin Lakes, USA 
Lys48-specific ubiquitin, clone Apu2 
(05-1307) 
rabbit 1:1000 250-16 
kDa 
Merck Millipore; Danvers, USA 
LC3B (D11) XP 
(3868) 
rabbit 1:1000 14, 16 kDa Cell Signaling; Danvers, USA 
Actin (anti-beta, Peroxidase (clone AC-15) 
(A3854) 
HRP-
conjugated 
1:40 000 42 kDa Sigma-Aldrich; Taufkirchen, Germany 
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Table 3.8: Secondary antibodies for Western blot 
Antibody Host Dilution Company 
HRP Linked Whole AB Rabbit IgG  
(NA934V) 
donkey 1:20 000 GE Healthcare; Freiburg, Germany 
HRP Linked Whole AB Mouse IgG  
(NA931V) 
sheep 1:20 000 GE Healthcare; Freiburg, Germany 
 
Table 3.9: Fluorochrome-conjugated antibodies for FACS analysis 
Antibody Host Dilution Company 
PDGFRα _ (CD140a)-PE 
(323505) 
mouse 1:5 BioLegend; San Diego, USA 
PDGFRβ _ (CD140b)-PE 
(323605) 
mouse 1:20 BioLegend; San Diego, USA 
PDGFRβ _ (CD140b)-APC 
(323608) 
mouse 1:10 BioLegend; San Diego, USA 
APC anti-human CD318 (CDCP1) 
 (324008) 
mouse 1:10 BioLegend; San Diego, USA 
 
Table 3.10: Isotype controls for FACS analysis 
Isotype Ctrl Host Dilution Company 
PE Mouse IgG1 
(400113) 
n.d. 1:20 / 1:10 BioLegend; San Diego, USA 
APC Mouse IgG1 
(400121) 
n.d. 1:3 BioLegend; San Diego, USA 
APC Mouse IgG2b  
(400320) 
n.d. 1:5 BioLegend; San Diego, USA 
 
Table 3.11: Primary antibodies for immunofluorescence stainings 
Isotype Ctrl Host Dilution Company 
CDCP1/CD318 
(PA5-17245) 
rabbit 1:100 ThermoFisher Scientific; Rockford, USA 
anti-human CD90 (Thy-1) 
(14-9090-82) 
mouse 1:100 eBioscience; San Diego, USA 
anti-actin, α-smooth muscle (αSMA)  
(A5228) 
mouse 1:5000 Sigma; St. Louis, USA  
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Table 3.12: Secondary antibodies for immunofluorescence stainings 
Isotype Ctrl Host Dilution Company 
Alexa Fluor 568 Goat Anti-Rabbit IgG (H+L) 
(A11011) 
goat 1:250 ThermoFisher Scientific; Rockford, USA 
Goat anti-Mouse IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 488  
(A11001) 
goat 1:250 ThermoFisher Scientific; Rockford, USA 
 
Table 3.13: Antibodies for immunoprecipitation 
Antibody Host Dilution Company 
CDCP1 
(4115) 
rabbit 1:1000 Cell Signaling; Danvers, USA 
 
 Human primers 
Table 3.14: Sequences of human primers 
Target gene Sequence 5' - 3' 
ACTA2 (αSMA) fw: CGAGATCTCACTGACTACCTCATGA 
rv: AGAGCTACATAACACAGTTTCTCCTTGA  
CDCP1 fw: TTCAGCATTGCAAACCGCTC 
rv: ATCAGGGTTGCTGAGCCTTC   
HPRT fw: AAG GAC CCC ACG AAG TGT TG 
rv: GGC TTT GTA TTT TGC TTT TCC A 
  
 Kits 
Table 3.15: Kits 
Product Company 
Pierce BCA Protein Assay Kit Biochrom; Berlin, Germany 
Dual luciferase reporter system Promega; Mannheim, Germany 
PeqGold RNA kit Peqlab; Erlangen, Germany 
Sircol collagen assay kit Biocolor; Northern Ireland, U.K. 
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 Laboratory equipment  
Table 3.16: Laboratory equipment 
Laboratory equipment Company 
-80°C freezer U570 HEF New Brunswick; Hamburg, Germany 
-20°C freezer MediLine LGex 410 Liebherr; Biberach, Germany 
2100 Antigen Retriever Aptum Biologics; Southamptom, U.K. 
Analytical scale XS20S Dual Range Mettler Toledo; Gießen, Germany 
Autoclave DX-45 Systec; Wettenberg, Germany 
Autoclave VX-120 Systec; Wettenberg, Germany 
AxioImager M2 Zeiss; Jena, Germany 
Axiovert 40C microscope Zeiss; Jena, Germany 
Cell culture work bench Herasafe KS180 Thermo Fisher Scientific; Darmstadt, Germany 
Centrifuge MiniSpin plus  Eppendorf; Hamburg, Germany 
Centrifuge Rotina 420R Hettich; Tuttlingen, Germany 
Centrifuge with cooling, Micro200R Hettich; Tuttlingen, Germany 
CO2 cell Incubator BBD6620 Thermo Fisher Scientific; Darmstadt, Germany 
Confocal microscope LSM 710 Zeiss; Jena, Germany 
Corning® LSE™ Mini Microcentrifuge, 120V Corning; Wiesbaden, Germany 
Demineralized water Thermo Fisher Scientific; Darmstadt, Germany 
Dry ice container Forma 8600 Series, 8701 Thermo Fisher Scientific; Darmstadt, Germany 
DynabeadsTM Protein A Thermo Fisher Scientific; Darmstadt, Germany 
DynaMagTM - 2 Magnet Thermo Fisher Scientific; Darmstadt, Germany 
Electronic pipet filler Eppendorf; Hamburg, Germany 
Film developer Curix 60 AGFA; Morsel, Belgium 
Fridge MediLine LKv 3912 Liebherr; Biberach, Germany 
Fisher Science Education™ 4-Way Microtube Racks Thermo Fisher Scientific; Darmstadt, Germany 
Gel imagine system ChemiDoc XRS+ Biorad; Hercules, USA 
Ice machine ZBE 110-35 Ziegra; Hannover, Germany 
Light Cycler LC480II Roche Diagnostic; Mannheim, Germany 
Liquid nitrogen cell tank BioSafe 420SC Cryotherm; Kirchen/Sieg, Germany 
BD LSR II Flow Cytometer BD; Franklin Lakes, USA 
Magnetic stirrer KMO 2 basic IKA; Staufen, Germany 
Mastercycler Nexus Eppendorf; Hamburg, Germany 
Microm HMS740 Robot-Stainer  Thermo Fisher Scientific; Darmstadt, Germany 
Multipette stream Eppendorf; Hamburg, Germany 
Nalgene® Freezing Container (Mr. Frosty) Omnilab; Munich, Germany 
NanoDrop 1000 PeqLab; Erlangen, Germany 
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pH meter InoLab pH 720 WTW; Weilheim, Germany 
Pipettes Research Plus Eppendorf; Hamburg, Germany 
Plate centrifuge 5430 Eppendorf; Hamburg, Germany 
Plate reader TriStar LB941 Berthold Technologies; Bad Wildbach, Germany 
Plate reader Sunrise Tecan; Crailsheim, Germany 
VWR® Tube Rotator and Rotisseries VWR International; Darmstadt, Germany 
Roll mixer VWR International; Darmstadt, Germany  
Power Supply Power Pac HC Biorad; Hercules, USA 
Scale XS400 2S Mettler Toledo; Gießen, Germany 
Shaker Duomax 1030 Heidolph; Schwabach, Germany 
Thermomixer compact Eppendorf; Hamburg, Germany 
Ultra-pure water supply MilliQ Advantage A10 Merck Millipore; Darmstadt, Germany 
Vortex Mixer IKA; Staufen, Germany 
Vacuum pump NO22AN.18 with switch 2410 KNF; Freiburg, Germany 
Water bath Aqua Line AL 12 Lauda; Lauda-Königshofen, Germany 
 
 Software 
Table 3.17: Software 
Product Company 
BD FACSDIVA™ BD Biosciences; Heidelberg, Germany 
FlowJo Software, Version 9.6.4 TreeStart Inc; Ashland, OR, USA 
GraphPad Prism 5 GraphPad Software; La Jolla, USA 
Imaris Scientific 3D/4D Image Processing and Analysis Software, 
Version 8.1.2 
Bitplane; Zurich, Switzerland 
Image Lab Software, Version 5.2.1 Biorad; Hercules, USA 
LightCycler® 480 SW 1.5 Roche Diagnostics; Mannheim, Germany 
Magelan Software Tecan; Crailsheim, Germany 
Tristar MicroWin 2000 Berthold Technologies; Bad Wildbach, Germany 
ZEN 2010 – Digital Imaging for Lightmicroscopy Software Zeiss; Oberkochen, Germany 
      
  Methods 
 Isolation of primary human lung fibroblasts 
Primary human lung fibroblasts (phLFs) were isolated from lung tissues derived from lung explants or 
tumor-free areas of lung resections provided by the CPC-M Bioarchive, Munich, Germany. This project 
was approved by the local ethics committee of the LMU Munich (333-10, removal request 454-12). For the 
MATERIALS AND METHODS 
35 
 
isolation procedure, the lung tissue explants were placed in a 10 cm dish containing prewarmed DMEM-
F12 media supplemented with 20% FBS and 100 U/ml of penicillin/streptomycin. Subsequently, tissue 
explants were subdivided into 1-2 mm2 pieces using scissors or scalpel, and thereafter transferred in a 50 ml 
falcon tube for further enzymatic digestion with 5 mg of Collagenase I (Biochrom) for 1 h at 37°C. 
Afterwards, the digested tissue pieces were filtered through 70 µm Nylon filters, and further washed with 
10 ml sterile 1x PBS for 5 min at 450g at 4°C. The supernatant was carefully aspirated and cell pellets 
resuspended in 10 ml DMEM-F12 media supplemented with 20 % FBS plus 100 U/ml of 
penicillin/streptomycin. Cells were subsequently plated on 10 cm cell culture dishes and cultured under 
standard cell culture conditions at 37°C and 5% CO2.  
 
 Cryopreservation of primary human lung fibroblasts 
For cryopreservation, phLFs were detached with 0.25 % Trypsin-EDTA and Cell suspension was transferred 
in a 50 ml falcon tube followed by centrifugation for 5 min at 450g at 4°C. Next, media was carefully 
aspirated and cell pellet immediately resuspended in freezing media (DMEM-F12, 70 % FBS, 100 U/ml of 
penicillin/streptomycin, and 10 % DMSO). Cell suspensions were transferred into cryovials, and stored in 
Mr. Frosty (Omnilab) overnight at –80°C. Next day, cryovials were transferred to liquid nitrogen for long-
term storage at -195°C. 
 
 Thawing frozen cells 
Cryovials with frozen cell suspensions were placed in a 37°C water bath for approximately 90 s until cell 
suspension defrosted followed by immediate dilution of the cell suspension with 1 ml prewarmed 20% 
DMEM-F12 media supplemented with 100 U/ml of penicillin/streptomycin. Defrosted cell suspension was 
transferred in a 50 ml falcon tube and carefully supplemented with 8 ml of cell culture media. Cells were 
then centrifuged for 5 min at 450 g at 37 °C, and the cell pellet was resuspended with fresh cell culture 
medium (20 % FBS, DMEM-F12, 100 U/ml of penicillin/streptomycin). Cells were plated in a 10 cm cell 
culture dish and cultured under standard cell culture conditions at 37°C and 5% CO2. 
 
 Cell culture experiments 
3.2.4.1 Growth factor stimulation 
PhLFs were seeded on a 6-well plate (2.6 x 104 cells/cm2) or a 10 cm cell culture dish (1.2 x 104 cells/cm2) 
in 20 % DMEM-F12 cell culture media supplemented with 100 U/ml of penicillin/streptomycin. Cells were 
serum starved the next day in 0.5 % DMEM-F12 media supplemented with 100 U/ml of 
penicillin/streptomycin for 24 h, and subsequently stimulated in starvation media with 1 ng/ml or 2 ng/ml 
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of human recombinant TGFβ1 either for 40 min or every 24 h for a total 48h treatment. Additionally, phLFs 
were stimulated with 10, 50, or 100 ng/ml recombinant human PDGF-AA, PDGF-AB, PDGF-CC, and 
PDGF-DD ligands for various time points starting from 40 min up to 24 h.  
 
3.2.4.2 siRNA-mediated reverse transfection 
All human siRNAs used in this study (Table 3.4) were purchased from Thermo Fisher Scientific as 
lyophilized products. Prior transfection, siRNAs were first dissolved in 50 µl sterile, DNase/RNase-free 
water in order to obtain 100 µM stock solutions. For the experimental procedures, the stock solutions were 
further diluted in 1:5 ratios to obtain 2 µM working solutions, and stored at – 20 °C degrees until further 
use. 
For the procedure, transfection mix containing solution A and B was prepared as described in Table 3.18.  
 
Table 3.18: Complete transfection mix per one well of a 6-well plate or one 10 cm dish 
Solution Reagent 
Volume (2 nM siRNA) 
6-well plate 
Volume (10 nM siRNA) 
6-well plate 
Volume (10 nM siRNA) 
10 cm dish 
A 
OptiMem media 247.5 µl 237.5 µl    760 µl 
siRNA      2.5 µl   12.5 µl      40 µl 
B 
OptiMem media    244 µl    244 µl 780.8 µl 
Lipofectamine® RNAiMax        6 µl        6 µl   19.2 µl 
 
Solutions A and B were first separately incubated for 5 min at RT, and then incubated together for 20 – 30 
min at RT in order to form siRNA-lipid complexes. Subsequently, transfection carried out in a 6-well plate 
was performed as follows: 500 µl of complete transfection mix was transferred to each well and mixed with 
2.5 ml of cell suspension containing 2.6 x 104 cells/cm2. On the other hand, transfection carried out in a 10 
cm dishes was performed by transferring 1.6 ml of complete transfection mix to each 10 cm dish and mixed 
with 8 ml of cell suspension containing 1.2 x 104 cells/cm2. Importantly, phLFs were seeded in 20% DMEM-
F12 cell culture media without penicillin/streptomycin. To test siRNA efficiency in phLFs, cells remained 
transfected for 24 h, 48 h, and 72 h. For the main experiment, 24 h after adding transfection mix, cells were 
starved in 0.5% DMEM-F12 starvation media supplemented with 100 of U/ml of penicillin/streptomycin 
overnight and treated with growth factors as described in section 3.2.4.1. 
 
3.2.4.3 Plasmid DNA transfection 
Per one well of a 48-well plate, 3.2 x 104 cells/cm2 were reversely transfected for 24 h with 10 nM siRNA 
against CDCP1 and control scrambled siRNA as described above (section 3.2.4.2). Subsequently, cells were 
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washed once with 1x PBS and refreshed with 200 µl 20% DMEM-F12 cell culture media supplemented 
with 100 U/ml of penicillin/streptomycin. Plasmid transfection was performed with 250 ng/ml of the SMAD 
signaling luciferase reporter plasmid pGL3-CAGA(9)-luc [Dennler et al., 1998] and control pGL4-10 
construct (Table 3.5). For plasmid transfection, 25 µl of solution A and B per one well were prepared as 
described in Table 3.19 and Table 3.20. Both solutions were separately incubated for 5 min at RT and 
afterwards incubated together for additional 20 – 30 min at RT. Subsequently, 50 µl of complete transfection 
mix per one well of a 48-well plate was transferred to respective wells, and plasmid transfection was 
performed for additional 6 h. Afterwards, cells were serum starved overnight in 0.5 % DMEM-F12 media 
containing antibiotics followed by stimulation with 1 ng/ml TGFβ for 1 h, 26 h, and 48 h. Finally, cells were 
washed once with 1x PBS and plates were stored at – 80°C until luciferase assay was performed. 
 
Table 3.19: Plasmid calculations 
Plasmid Concentration Volume 250 ng/well 
pGL4-10 2.0 mg/ml 0.125 µl 
pGL3-CAGA(9)-luc 1.4 mg/ml 0.18 µl 
 
 
Table 3.20: Complete transfection solution per one well of a 48-well plate 
Plasmid Solution Reagent Volume  
 
pGL4-10 
 
Solution A 
OptiMem media 25 µl 
Plasmid   0.125 µl 
PLUS reagent   0.25 µl 
Solution B 
OptiMem media 25 µl 
Lipofectamine LTX   0.6 µl 
 
pGL3-CAGA(9)-luc  
 
Solution A 
OptiMem media 25 µl 
Plasmid   0.18 µl 
PLUS reagent   0.25 µl 
Solution B 
OptiMem media 25 µl 
Lipofectamine LTX   0.6 µl 
 
3.2.4.4 Luciferase reporter assay 
Fortyeight hours after plasmid transfection (section 3.2.4.3), phLFs were lysed with 65 µl per well of Glo 
Lysis Buffer (Promega) for 30 min at RT while incubating at an orbital shaker. Thereafter, 25 µl of cell 
lysate was transferred in a white 96-well microplate and luciferase activity was quantified by incubation of 
cell lysates with 100 µl Bright-GloTM luciferase assay substrate in a plate reading luminometer with an 
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automatic injection system (Berthold). All measurements were carried out in quadruplicates and all 
treatment conditions were normalized to control scrambled siRNA measurement.  
 
3.2.4.5 Cell treatment with inhibitors 
Cells were plated in a density of 2.6 x 104 cells/cm2 in DMEM-F12 media containing 20 % FBS and 100 
U/ml of penicillin/streptomycin. Next day, cells were starved with DMEM-F12 media containing 0.5 % 
FBS plus 100 U/ml of penicillin/streptomycin 24 h prior the treatment. Thereafter, cells were stimulated 
with individual inhibitors or antagonists enlisted in Table 3.6. Nintedanib stimulation was performed by 
treating cells either with 1 µM Nintedanib for 30 min followed by cell stimulation with 10 ng/ml PDGF-
AB, PDGF-DD, or 1 ng/ml TGFβ1 for 40 min, or in parallel with 1 or 2 ng/ml TGFβ every 24 h for a total 
of 48 h. Else, cells were treated with single inhibitors in the presence of 1 ng/ml TGFβ every 24 h for a total 
of 48 h treatment. 
 
3.2.4.6 Cell treatment with 2-phospho-L-ascorbic acid 
Cells were treated as described in section 3.2.4.5 with media further supplemented with 0.1 mM 2-phospho-
L-asorbic acid. 
 
3.2.4.7 Cell adhesion assay 
Treated phFLs cells as described in section 3.2.4.2 were harvested and 1.1 x 104 cells/cm2 plated in a 48-
well plate in quadruplicates. Cells were resuspended in 0.5% starvation DMEM-F12 media and allowed to 
attach for 10 min at 37°C under humidified cell culture conditions. Afterwards, non-adherent cells were 
removed by washing the wells with 1x PBS. Adherent cells were fixed with 4% PFA for 15 min at RT, 
washed twice with 1x PBS, and incubated with DAPI (nuclear staining) and Phalloidin (cytoskeletal 
staining) for 1 h at RT. Cells were again washed three times with 1x PBS, and finally stored in 1x PBS at 
4°C. For the analysis, each well was individually scanned with an LSM710 confocal microscope and images 
were acquired by an 8x8 tile scan covering the middle area of each well. Data were quantified by Imaris 
software version 8.1.2. (Bitplane). 
 
3.2.4.8 Cell invasion assay 
3.2.4.8.1 Preparation of collagen G Gels 
Collagen G Gels were prepared according to the manufacturer's instructions (Biochrom AG). Briefly, 
solution A was prepared by mixing 0.7 M NaOH together with 1 M HEPES buffer (Sigma Aldrich) in a 1:1 
ratio. Thereafter, 10x PBS supplemented with 20 % FCS was added to the solution A in a 1:1 ratio, forming 
a solution B with pH 7.90 - 8.05. For a final gelation step, solution B was thoroughly mixed with collagen 
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G in a ratio 1:4. Importantly, all solutions were kept and prepared on ice during the whole procedure. For 
the invasion assay, 40 µl of collagen G solution was poured in each well of a 96-well image plate, and 
polymerization of the final collagen G gels was achieved by incubation at 37°C for 1 h. The quality of 
collagen G gels was examined with an Axiovert 40C microscope (Carl Zeiss).  
 
3.2.4.8.2  3D collagen-based invasion assay 
Cell were plated in a density of 5.8 x 104 cells/cm2 on the top of polymerized collagen G matrix (section 
3.2.4.8.1). Cells were plated in DMEM-F12 media supplemented with 5% FBS and 100 U/ml of 
penicillin/streptomycin, and starved overnight in media containing 0.5% FBS. Subsequently, cells were 
stimulated with 10 ng/ml PDGF-AA, PDGF-AB, and PDGF-DD ligands (five technical replicates per 
stimulation) and left for invasion into collagen gels for 48 h under standard cell culture conditions (at 37°C 
and 5% CO2). The collagen matrices were carefully washed once with 1x PBS, fixed with 4% PFA for 45 
min at 37°C, and subsequently stained with DAPI (1:1500) and Phalloidin (1:300) in 1x PBS for 1 h at RT. 
Phalloidin staining was used to visualize the cell layer, and to estimate cell confluency. DAPI was used to 
visualize cell nuclei. Finally, cells were washed twice with 1x PBS and an LSM710 confocal microscope 
was used to image each well containing phLFs embedded in a 3D collagen gels. The exact settings and 
parameters for image acquisition as well as final data quantification were previously described in Burgstaller 
et al., 2013 [Burgstaller et al., 2013].  
 
 Protein analysis 
3.2.5.1 Protein extraction from primary fibroblasts 
Cells attached on a 6-well plate were washed with 1x PBS and subsequently scratched with a cell scraper in 
80 µl of a RIPA protein lysis and extraction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 
0.5% Sodium – deoxycholate, and 0.1% SDS) supplemented with 1x Roche complete mini protease 
inhibitor cocktail and PhosphoStop phosphatase inhibitor (per one well of a 6-well plate). Cell lysates were 
transferred in a 1.5 ml reaction tube, placed on ice and incubated in complete RIPA buffer for 30 min. 
Subsequently, cell lysates were centrifuged for 15 min at 15.000 RPM at 4°C to separate total protein content 
(supernatant) from cell debris (pellet). Cell supernatants were stored at -80°C. Protein concentration was 
determined using the Pierce BCA Protein Assay Kit according to the manufacturer’s instructions.  
 
3.2.5.2 Protein concentration from cell supernatants 
Cell supernatants were thawed on ice and Amicon Ultra-0.5 Centrifugal Filter Devices (Millipore) were 
used to concentrate cell supernatants according to the manufacturer's instructions. Briefly, 500 µl per sample 
was transferred into an Amicon Ultra 3k Centrifugal Filter Unit inserted into microcentrifuge tube and 
MATERIALS AND METHODS 
40 
 
samples were centrifuged for 30 min at 14.000 g at 4°C. To recover the concentrated proteins, Amicon Ultra 
3k Centrifugal Filter Unit was inverted and placed in a new clean microcentrifuge tube followed by 
centrifugation for 2 min at 1000 g at 4°C. Finally, the ultrafiltrate was stored in the centrifuge tube at -80°C 
for further analysis.  
 
3.2.5.3 SDS-PAGE and immunoblotting 
4% stacking and 7.5 % or 10 % separation gels were prepared as described in the Table 3.21 and Table 3.22. 
For protein separation via SDS-PAGE electrophoresis, samples from total protein lysates were prepared by 
mixing 25 µg of total protein lysates with 2x or 6x Laemmli loading buffer in Millipore-H2O for equal 
volumes. Samples from concentrated cell supernatants were prepared by mixing 60 µl of cell supernatants 
together with 10 µl of 6x Laemmli loading buffer. Finally, samples were incubated for 5-10 min at 95°C.  
 
Table 3.21: Composition of 4 % SDS-PAGE Stacking gel 
Reagent Volume 
Millipore-H2O 1.50 ml 
0.5 M Tris-HCl pH 6.8 630 µl 
10 % SDS 30 µl 
Acrylamide/Bisacrylamide 330 µl 
TEMED 2 µl 
10 % APS 13 µl 
 
Table 3.22: Composition of 7.5 % and 10 % SDS-PAGE Separation gels 
Reagent 
7.5 % 10 % 
Volume Volume 
Millipore-H2O 4.36 ml 3.61 ml 
1.5 M Tris-HCl pH 8.8 2.25 ml 2.25 ml 
10 % SDS 90 µl 90 µl 
Acrylamide/Bisacrylamide 2.25 ml 3 ml 
TEMED 7.2 µl 7.2 µl 
10 % APS 45 µl 45 µl 
 
Proteins were further separated on 7.5 % or 10 % SDS-polyacrylamide gels at 120 V per gel for 
approximately 1.5 h. For immunoblotting, protein samples were transferred to a methanol-activated 
polyvinylidenedifluoride (PVDF, Millipore, 0.45 µm) membrane at 240 mA per gel for 90 min. Membranes 
were blocked with 5 % non-fat dry milk prepared in 1x TBST (0.1% Tween®20 / 10x TBS) for 30 min at 
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RT, followed by incubation with primary antibodies overnight at 4 °C while rotating. Membranes were 
washed three times with 1x TBST for 10 min and subsequently incubated with respective HRP-conjugated 
secondary antibodies for 1 h at RT while rotating. Afterwards, membranes were again washed three times 
with 1x TBST for 10 min and proteins were visualized by using western blot chemiluminescent substrates 
(SuperSignal® West Dura and Femto Substrate, Thermo Fisher). Signals were analyzed with the film 
developer Curix60 (AGFA) and finally documented on x-ray films. For densitometry quantification, x-ray 
films were first scanned using ChemiDoc Imaging System (Bio-Rad) and protein quantity was measured 
using Image Lab Software (Bio-Rad). 
 
3.2.5.4 Immunoprecipitation 
1.4 x 104 cells/cm2 were treated as described in section 3.2.4.5, washed with 1x PBS and subsequently 
scratched with cell scraper in 2-3 ml of 1x PBS. Cell pellets were afterwards stored in a 1.5 ml reaction tube 
at -80°C for further analysis.  
First, DynabeadsTM Protein A (Thermo Fisher Scientific) magnetic beads were equilibrated as follows: beads 
were gently vortexed, transferred in 1.5 ml Protein LoBind Tubes (Eppendorf) and subsequently washed 
three times with 500 μl of ice-cold RIPA protein lysis and extraction buffer supplemented with 1x Roche 
complete mini protease inhibitor cocktail and PhosphoStop phosphatase inhibitor. Each time, 500 μl of 
complete RIPA buffer was added to beads followed by inverting a tube for approximately 10x. Lysis buffer 
was then discarded by placing a reaction tube on a DynaMagTM -2 magnet (Thermo Fisher Scientific), where 
magnetic beads remained on the wall of a tube and thus lysis buffer could be carefully pipetted away. 
Magnetic beads were finally resuspended in a 500 µl of lysis buffer.  
For immunoprecipitation, cell pellets were lysed in 500 µl of RIPA protein lysis and extraction buffer 
supplemented with 1x Roche complete mini protease inhibitor cocktail and PhosphoStop phosphatase 
inhibitor. Cell pellets were placed on ice and incubated in complete RIPA buffer for 30 min followed by 
centrifugation for 15 min at 15.000 RPM at 4°C to separate total protein content (supernatant) from 
intracellular cell debris (pellet). A preclearing step of the cell lysate was performed by incubating with 75 
μl of equilibrated magnetic DynabeadsTM Protein A for 1 h at 4°C while rotating. Subsequently, suspension 
was centrifuged for 1 min at 800g at 4°C and placed on a DynaMagTM -2 magnet with magnetic beads 
remained on the wall of reaction tubes. Thus, 100 μl of whole protein lysate was pipetted away and stored 
at -80°C as an input (20 % of whole cell lysate). Remaining protein lysates were subsequently transferred 
in new 1.5 ml Protein LoBind Tubes and precleared beads also stored at -80°C for further analysis. 
Afterwards, 0.4 μg of antibody directed against CDCP1 or respective rabbit IgG control were added to 
protein lysates and incubated for 1 h on ice. Finally, 45 μl of equilibrated magnetic beads were added to 
each reaction tube followed by incubation of the mix overnight at 4°C using VWR® Tube Rotator. Next 
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day, the whole suspension was centrifuged for 1 min at 800g at 4°C and supernatant collected by placing 
the tubes on a DynaMagTM -2 magnet. Supernatant was stored at -80°C for further analysis. Magnetic beads 
containing immunoprecipitated CDCP1 were washed three times in 500 μl of ice-cold NP-40 wash buffer, 
each time for 5 min at 4°C under continuous inverting. Reaction tubes were then placed on a DynaMagTM -
2 magnet, to completely remove the wash buffer. Finally, immunoprecipitants were resuspended in 35 μl of 
2x Laemmli buffer, incubated for 10 min at 95°C and analyzed via immunoblot as described in section 
3.2.5.3.  
 
3.2.5.5 Sircol collagen assay 
Cells were treated as described in section 3.2.4.6 and 1 ml of cell supernatant from treatments were stored 
in 1.5 ml Protein LoBind Tubes (Eppendorf) at -80°C. Importantly, the whole Sircol collagen assay was 
carried out on ice. 
Collagen Standards were prepared according to manufacturer's instructions (Bicolor). Cell supernatants 
were thawed on ice, and proteins from cell supernatants were concentrated as described in chapter 3.2.5.2. 
Subsequently, 200 μl of ice cold Isolation and Concentration Reagent was added to 1 ml of cell supernatant 
(test sample, duplicates), 1 ml of standard dilution (Collagen Standard, duplicates), and to 1 ml of starvation 
medium containing 0.1 mM ascorbate (Blank, duplicates). Reaction tubes were well mixed by inverting 
approximately10x and subsequently placed into a container half filled with an ice-water mix for overnight 
incubation at 4°C. Next day, reaction tubes containing collagen precipitates were centrifuged for 30 min at 
14.000 RPM at 4°C and supernatants afterwards carefully discarded by inverting each reaction tube. 
Transparent pellets of hydrated collagen remained on the bottom of reaction tubes. Next, 1 ml of Sircol Dye 
Reagent was added to each reaction tube which was mixed well by inverting, followed by incubation of 
each reaction tube for 30 min at 400 RPM at RT in a Thermomixer under gentle shaking. Afterwards, 
reaction tubes were centrifuged for 30 min at 14.000 RPM and supernatant was removed by inverting each 
reaction tube. Inverted tubes were dried on tissues and cotton buds were used to remove unbound dye from 
inside walls of reaction tubes while dye-bound collagen precipitates remained on the bottom of each tube. 
Afterwards, 750 μl of ice-cold Acid-Salt Wash reagent was added to the pellet and the reaction mix 
centrifuged for 30 min at 14.000 RPM at RT. Wash solution was again carefully removed as described 
above and the washing step repeated one more time. Finally, 250 μl of Alkali Reagent was added to each 
reaction tube and pellets containing precipitated dye-bound collagens were dissolved by vortexing. Once all 
bound dye was dissolved, 200 μl of each sample was transferred in duplicates to a 96-well plate and the 
absorbance of each samples measured at 550 nm using Sunrise Plate Reader (Tecan). 
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3.2.5.6 Immunofluorescence staining of primary human lung fibroblast  
PhLFs were seeded in a 96-well image plate (BD Falcon) or a 24-well image plate (Ibidi) and cultured till 
a confluency of 80 %. Cells were washed once with 1x PBS and subsequently fixed either with 4% PFA in 
PBS for 15 min at RT or with 100% ice-cold methanol for 90s on ice. Methanol fixation was at the same 
time used for cellular permeabilization to access intracellular antigens. After fixation step, cells were washed 
twice with 1x PBS followed by incubation with 5% BSA in 1x PBS for 30 min at RT. Subsequently, cells 
were stained with primary antibody against CDCP1, CD90 (Thy-1), and αSMA for 1 h at RT. Afterwards, 
cells were washed three times with 1x PBS for 5 min at RT, and incubated with fluorescently-labeled 
secondary antibody AlexaFluor 568 and AlexaFluor 488 in parallel with DAPI (nuclei visualization) for 45 
min at RT in darkness. Subsequently, cells were washed three times with 1x PBS, and antibody stainings 
were fixed again either with 4% PFA in PBS for 15 min at RT or 100% ice-cold methanol for 90s on ice. 
Finally, cells were washed once with 1x PBS and kept in 1x PBS until further analysis using an LSM710 
laser scanning microscope (Carl Zeiss). Images were acquired using the ZEN 2010 software (Carl Zeiss). 
 
3.2.5.7 Immunofluorescence staining of spherically-shaped primary human lung fibroblasts 
PhLFs were seeded in a density of 1.2 x 104 cells/cm2 on cell culture dishes and cultured until 95% 
confluency. Subsequently, cells were washed with 1x PBS, trypsinized with 0.25% Trypsin-EDTA (Gibco), 
and finally neutralized with 20% DMEM-F12 cell culture media. Afterwards, 0.2 x 106 cells were 
transferred in sterile 2 ml reaction tubes, centrifuged for 5 min at 450g at 4°C, and remaining media was 
aspirated. Cell pellets were washed with 1x PBS, centrifuged again for 5 min at 450g at 4°C, and PBS was 
aspirated. Next, cells were resuspended in 4% PFA in PBS for 15 min at RT, centrifuged for 5 min at 450g 
at 4°C and washed twice with 1x PBS again through centrifugation step. Subsequently, cell pellets were 
incubated with 5% BSA in 1x PBS for 30 min at RT, and blocking agent was removed through centrifugation 
for 5 min at 450g at 4°C. Cells were then incubated with antibodies as described under section 3.2.5.6. Cells 
were kept in 1x PBS until further analysis using an LSM710 laser scanning microscope (Carl Zeiss). Images 
were acquired using the ZEN 2010 software (Carl Zeiss).  
 
3.2.5.8 Live-cell staining  
For live-cell staining prior fixation, 0.2 x 106 cells were transferred in sterile 2 ml reaction tubes and cell 
suspension was incubated with Vybrant CFDA Cell Tracker dye (AlexaFluor 488, 1:2000, Molecular 
Probes) for 15 min at 37°C under humidified condition with 5% CO2. Thus, initially colorless Vybrant 
CFDA Cell Tracker dye passively diffused into live cells and underwent enzymatic conversion by which 
cell cytosol remained labeled with green color. Immediately afterwards, cell suspension was centrifuged for 
5 min at 450g at 4°C, and cell pellets were resuspended and incubated in a fresh 20% DMEM-F12 cell 
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culture media for 30 min at 37°C under humidified condition with 5% CO2. Cell suspension was then 
centrifuged for 5 min at 450g at 4°C, cell pellets resuspended and washed twice with 1x PBS under 
centrifugation. Subsequently, cell pellets were fixed, but not permeabilized, with prewarmed 4% PFA in 
PBS for 15 min at RT, washed twice with 1x PBS as described above, and immunofluorescence staining of 
spherically shaped phLFs performed with a CDCP1-specific antibody as described in section 3.2.5.7. Cells 
remained in 1x PBS until further analysis using an LSM710 laser scanning microscope (Carl Zeiss). Images 
were acquired using the ZEN 2010 software (Carl Zeiss).  
 
3.2.5.9 Immunofluorescence staining of paraffin-embedded tissue sections 
The paraffin-embedded lung tissue sections from healthy donors and IPF patients were first placed at 60°C 
overnight followed by tissue deparaffinization and hydration using a Microm HMS 740 Robot-Stainer 
(Thermo Fisher Scientific). Here, tissue slides were automatically transferred and incubated with different 
chemicals as described in the Table 3.23.  
 
Table 3.23: Deparaffinization protocol 
Description  Reagent Cycles Time 
Deparaffinization step Xylene  2x 5 min 
Hydration step 
100% ethanol 2x 2 min 
90% ethanol 1x 1 min 
80% ethanol 1x 1 min 
70% ethanol 1x 1 min 
dH2O 1x 30 sec 
 
Afterwards, tissue sections were placed into R-Universal buffer (Aptum Biologics) followed by antigen 
retrieval in a decloacking chamber (2100 Retrieval, Aptum Biologics) for 20 min with 2 h of cooling down 
step to complete the program. Subsequently, slides were washed three times in Tris buffer (0.5 M Tris, 1.5 
M NaCl, pH 6.8) for 10 min, then incubated in 5% BSA in PBS for 40 min at RT, and subsequently stained 
with primary antibody against CDCP1, and αSMA overnight at 4°C under humid conditions. Next day, 
slides were washed three times in Tris buffer (0.5 M Tris, 1.5 M NaCl, pH 6.8) for 10 min, and subsequently 
incubated with fluorescently-labeled secondary antibody AlexaFluor 568 and AlexaFluor 488 for 1 h at RT 
under humid conditions. Following three additional washes, slides were counterstained with DAPI for 10 
min at RT, washed again three times in Tris buffer (0.5 M Tris, 1.5 M NaCl, pH 6.8) for 10 min and 
subsequently let dried at RT. Finally, tissue slides were mounted with Fluorescent Mounting Medium 
(DAKO) and stored at 4°C until further analysis. Tissue slides were visualized using Axio Imager 
Microscope (Carl Zeiss) and images acquired using the ZEN 2010 software (Carl Zeiss).  
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3.2.5.10  Flow cytometry 
PhLFs were treated as described in sections 3.2.4.1 or in 3.2.4.2. Cells were then washed with 1x PBS, 
afterwards detached with 0.25% Trypsin-EDTA and subsequently neutralized with prewarmed 20% 
DMEM-F12 cell culture media. Next, cell suspension containing 2.5 x 105 cells per test was centrifuged for 
5 min at 450g at 4°C and cells were once washed with 1x PBS, and MACS buffer. Cells were resuspended 
and incubated in MACS buffer containing TruStain FcXTM for 10 min at RT. Subsequently, cells were 
transferred in a 96-well plate with round bottom, centrifuged for 5 min at 450g at 4°C, and afterwards cell 
pellets stained with PE-conjugated antibodies against PDGFRα, PDGFRβ (both Biolegend), APC-
conjugated CDCP1 antibody (Biolegend), or corresponding isotype controls in the same concentration for 
20 min at 4°C. Cells were afterwards washed three times with MACS buffer as described above, fixed with 
4% PFA for 15 min at RT, washed once more with MACS buffer and finally 350 µl of cell suspension was 
used for FACS analysis (LSRII, BD). Number of positive cells and median fluorescent intensity were 
determined using FlowJo software version 9.6.4. 
 
 RNA expression analysis 
3.2.6.1 RNA isolation  
The peqGOLD Total RNA Kit was used to isolate total RNA from fibroblasts according to the 
manufacturer's instructions (Peqlab). Total RNA was eluted in 35 µl of pre-warmed DNase/RNase-free 
dH2O. The concentration of isolated RNA was determined at a wavelength of 260 nm using NanoDrop 
1000.   
 
3.2.6.2  cDNA synthesis by Reverse Transcription  
For cDNA synthesis, 1 µg of isolated RNA was first diluted in 18 µl of DNase/RNase-free dH2O and 
subsequently subjected for denaturation in an Eppendorf Mastercycler using the following settings: 
lid=45°C, 70°C for 10 min and 4°C for 5 min. Afterwards, components of the GeneAMP PCR kit (Applied 
Biosystems) were added to the mix according to Table 3.24, and reverse transcription was carried out in an 
Eppendorf Mastercycler with the following settings: lid=105°C, 20°C for 10 min, 42°C for 60 min and 99°C 
for 5 min. Finally, cDNA was diluted in 1:4 ratios with DNase/RNase-free dH2O and stored at – 20°C.  
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Table 3.24: Mastermix for cDNA synthesis 
Reagent Stock concentration 
Final concentration (40 µl) Final volume 
(µl) 
10x PCR Buffer II 10x 1x 4 
MgCl2 solution 25 mM 5 mM 8 
PCR Nucleotide Mix (dNTP) 10 mM 1 mM 4 
Random Hexamers 50 µM 2.5 µM 2 
RNase Inhibitor 20 u/µl 1 u/µl 2 
MuLV Reverse Transcriptase 50 u/µl 2.5 u/µl 2 
Denaturated RNA - - 18 
Total volume of the mastermix   40 
 
3.2.6.3 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
10 µl of reaction mix containing cDNA, primer mix, and SYBR green I Master Mix was prepared according 
to Table 3.25. qRT-PCR was carried out in a LightCycler® 480II (Roche) according to the standard PCR 
protocol summarized in the Table 3.26. Denaturation, annealing and elongation step were repeated in 45 
cycles. All qPCR assays were performed in triplicates and relative mRNA expression was normalized to 
HPRT housekeeper gene expression. Relative transcript abundance of target gene is presented as -ΔCp 
values (-ΔCp = Cp(target gene) – Cp(houskeeper gene)). 
 
Table 3.25: qPCR reaction mix per one assay 
 Reagent Stock concentration Final concentration  Final volume (µl) 
DNase/RNase-free H2O - - 1 
SYBR green I Master Mix 2x 1x 5 
Forward/Reverse Primer Mix 10 µM each 0.5 µM each 2 
cDNA 6.25 ng/µl 12.5 ng/µl 2 
Total volume of the reaction mix   10 
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Table 3.26: Standard qRT-PCR protocol 
Cycle step Temperature Duration 
Initial denaturation 95°C 5 min 
Denaturation 95°C 5 s 
Annealing 59°C 5 s 
Elongation 72°C 20 s 
Melting curve 60 – 95°C 1 min 
Cooling down  4°C on hold 
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4 RESULTS 
 
Chapter A: TGFβ regulates cell surface marker expression 
The first aim of my thesis was to corroborate the potential effect of TGFβ on PDGFRα and CDCP1 
expression levels and to determine their subcellular localization in phLFs. To achieve this, cells were treated 
in the presence or absence of TGFβ and the expression changes and surface localization of both markers 
monitored via qRT-PCR, immunoblot, FACS and immunofluorescent microscopy. 
 
 TGFβ decreases PDGFRα expression in phLFs 
Immunoblot analysis showed a significant downregulation (p<0.01) of PDGFRα protein expression after 48 
h of TGFβ treatment (Figure 4.1 A, B). The efficacy of TGFβ treatment was confirmed by increased αSMA 
protein expression (Figure 4.1 A, C).   
 
 
 
 
 
Figure 4.1: TGFβ downregulates PDGFRα expression in phLFs. (A) Immunoblot analysis of PDGFRα and αSMA expression 
in the whole cell lysates upon TGFβ treatment (1 ng/ml, 48 h). Shown is one representative blot with four biological replicates 
(n=4). (B, C) Densitometric quantification of eight biological replicates (n=8) was used to determine PDGFRα/β-actin and αSMA/β-
actin ratio. Data shown as mean ± SEM. Statistical analysis: Paired two-tailed t-test. **p-value < 0.01. 
 
To further investigate whether downregulation of PDGFRα whole protein levels also impacts cell surface 
localization, FACS analysis was used to determine the percentage of PDGFRα-positive cells upon TGFβ 
treatment. Here, TGFβ-treated cells displayed a significant decrease in the percentage of PDGFRα-positive 
cells (7.4% ± 10.1) when compared to non-treated cells (33.7% ± 11). In contrast, the numbers of PDGFRβ 
positive cells significantly increased by TGFβ treatment (81.4% ± 8.1) compared to non-treated cells (52.2% 
± 13.8) (Figure 4.2 A, B). Likewise, the same pattern was observed for the median fluorescence intensity 
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(MFI) values, which decreased for PDGFRα (71.0 ± 30.0 to 16.0 ± 14.0) and increased for PDGFRβ (211.0 
± 113.0 to 550.0 ± 263.0) among all cells (Figure 4.2 C).  
 
 
 
Figure 4.2: TGFβ decreases PDGFRα expression on the surface of phLFs. FACS analysis was used to determine the percentage 
of PDGFRα and PDGFRβ positive cells in the presence or absence of TGFβ (1 ng/ml, 48 h). (A) Histogram and dot blot with the 
isotype control labeled in red and the PDGFRα- or PDGFRβ-positive population in blue. (B) Quantification of PDGFRα- and 
PDGFRβ-positive cells from (A) as a summary of ten to twelve independent experiments with mean ± SD (n=10-12). (C) The 
respective median fluorescence intensity (MFI) values (ΔMFI) were calculated by the subtraction of the isotype MFI values. Shown 
is a summary of MFI values for PDGFRα, PDGFRβ and isotype control from ten to twelve independent experiments (n=10-12). 
Statistical analysis: Paired two-tailed t-test. ***p-value < 0.001. 
 
 TGFβ downregulates CDCP1 expression in phLFs 
CDCP1 has never been described in human lung fibroblasts to date. We therefore first examined its 
expression and localization in phLFs via immunofluorescence stainings. Here, I demonstrated for the very 
first time CDCP1's cells surface expression (Figure 4.3 A), as well as co-localization with CD90 (Thy-1), a 
commonly accepted cell surface marker for mesenchymal cells. This was observed on the surface of PFA-
fixed cell monolayers (Figure 4.3 B) as well as on the surface of detached, and thus spherically shaped lung 
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fibroblasts (Figure 4.3 C). To further support this observation, trypsinized phLFs were labeled with 
Vybrant® CFDA SE intracellular dye, and the surface localization of CDCP1 imaged via 3-dimensional z-
stack sections (Figure 4.3 D). 
 
 
 
Figure 4.3: CDCP1 co-stains with CD90 (Thy-1) on the surface of phLFs. Representative stainings of monolayer phLFs (A) 
single stained with CDCP1 (red) or (B) double-stained with CDCP1 (red) and CD90 (green). (C) Representative stainings of 
spherically shaped phLFs double-stained with CDCP1 (red) and CD90 (green). (D) Orthoview of a confocal z-stack section 
demonstrating spherically shaped phLFs labeled intracellularly with Vybrant CFDA dye (green) and on the cell surface 
immunostained with CDCP1 (red). In each case, cell nuclei were counterstained with DAPI (blue). Images are presented as one 
representative staining of three technical replicates from three independent experiments (n=3). Scale bars: (A) 200 µm, (B) 10 µm, 
(C) 20 µm, (D) 10 μm. 
 
Next, I analyzed the effect of TGFβ on CDCP1 expression in general and determined the timepoint of 
significant expression change. TGFβ significantly decreased CDCP1 on mRNA (2.9-fold) and protein (2.8-
fold) levels as shown by qRT-PCR (Figure 4.4 C) and immunoblot (Figure 4.4 D, E) analysis, respectively. 
The efficacy of TGFβ treatment was confirmed by increased gene (Figure 4.4 C) and protein (Figure 4.4 A, 
B and D) expression of αSMA. Further, downregulation of CDCP1 protein was first observed after 24 h and 
the strongest effect after 48 h (Figure 4.4 A, B). Furthermore, TGFβ-treated cells displayed a significant 
decrease in the percentage of CDCP1-positive cells (73.5% ± 14.8) compared to non-treated cells (85.7% ± 
10.0) as shown by FACS analysis (Figure 4.4 E, F). Similarly, the median fluorescence intensity (MFI) 
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values significantly decreased for CDCP1 among all cells (1559.1 ± 1172.0 to 585.9 ± 351.2) (p<0.05) in 
the presence of TGFβ for 48 h (Figure 4.4 F). 
 
 
 
Figure 4.4: CDCP1 is downregulated by TGFβ in phLFs. (A) Immunoblot analysis of CDCP1 and αSMA expression in the 
whole cell lysates treated with 1 ng/ml TGFβ at indicated time points. Shown is one representative blot out of four independently 
performed experiments (n=4). (B) Densitometric quantification from (A) presented as mean ± SEM. (C) qRT-PCR and (D) 
immunoblot analysis of CDCP1 and αSMA expression from phLFs treated with TGFβ for 48 h. HPRT was used as a housekeeping 
gene. (E) Densitometric analysis of CDCP1 and αSMA expression from (D) depicted as mean ± SEM from five independent 
experiments (n=5). (F) FACS analysis evaluating changes in the percentage of CDCP1 positive cells in the presence or absence of 
TGFβ for 48 h. Representative histograms and dot blots are shown. The isotype control is depicted in red and the CDCP-positive 
cell population in blue. (E) Percentage of CDCP1-positive cells (left graph) shown as a summary of seven independent experiments 
with mean ± SEM (n=7). The median fluorescence intensity (MFI) values (right graph) were calculated by subtraction of the MFI 
RESULTS 
52 
 
values from isotype control. Data were obtained from seven independent experiments (n=7). Statistical analysis for each experiment: 
Paired two-tailed t-test. ***p-value<0.001, **p-value < 0.01, *p-value < 0.05.  
 
Chapter B: Functional consequence of altered surface marker expression 
Fibroblasts are the most important cell types producing ECM in the lung. TGFβ induces fibroblast-
myofibroblast transdifferentiation, which leads to αSMA-expressing myofibroblasts with increased ECM 
secretion. Nevertheless, little is known about specific receptors controlling this process beside TGFβ 
receptors. PDGF receptors and their signaling are well-known to play a role in IPF. On the other hand, the 
role of CDCP1 in lung fibroblasts and IPF has never been described to date. Thus, in the second part of my 
thesis I aimed to investigate a functional consequence of altered PDGFRα and CDCP1 expression by TGFβ 
in lung fibroblasts and IPF, particularly in the context of myofibroblasts activation and ECM production.  
 
 Characterization of PDGF signaling in lung fibroblasts and analysis of potential cross-talk to 
TGFβ signaling 
 
 PDGF ligands promote downstream PDGF signaling in lung fibroblasts 
To study the effect of single PDGF ligands on PDGF signaling in phLFs, cells were stimulated with PDGF-
AA, PDGF-AB, PDGF-CC, or PDGF-DD in a dose- and time-dependent manner, and phosphorylation 
levels of Akt (pAkt), a downstream mediator of PDGF signaling, assessed via immunoblot. Increased pAkt 
levels were already observed with 10 ng/ml for each ligand (Figure 4.5 A). The strongest increase was 
detected by PDGF-AB and PDGF-DD stimulation after 40 min (Figure 4.5 B), indicating that these two 
ligands mainly drive the signaling in phLFs 
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Figure 4.5:  PDGF signaling in human lung fibroblasts. PhLFs were treated with PDGF ligands (A) in a concentration-dependent 
manner and (B) over time as indicated above and the phosphorylation and total levels of Akt in the whole protein lysates determined 
via immunoblot. (B) Of note, time points 0 and 24 h (for PDGF-AA and -AB interpreted in the first and second band; for PDGF-
CC and -DD interpreted in the first and last band) were used to monitor pAkt levels under non-stimulated conditions. As this was a 
pilot test, the experiment was performed only once (n=1).  
 
 PDGF-AB increases invasion properties of primary human lung fibroblasts 
PDGF signaling has been described to be involved in cellular processes, such as invasion and proliferation 
[Heldin, 2013; Oehrle et al., 2015]. To investigate whether PDGF ligand-specific signaling, affects invasion 
properties of phLFs, we seeded phLFs on the top of a collagen G matrix, serum starved overnight, and 
subsequently left for invading into a matrix after incubation with 10 ng/ml of PDGF-AA, PDGF-AB, and 
PDGF-DD for 48 h (Figure 4.6 A).  
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Figure 4.6: PDGF-AB signaling plays a role in invasion properties of phLFs. (A) A schematic illustration of a 3D collagen 
invasion assay. (B) Spot analysis of invading phLFs presented as snapshot image. The non-invading population remained on the 
top of a collagen matrix whereas invading cells can be found within the collagen matrix. Scale bar: 10 μm. (C) Quantification and 
statistical analysis of six to eight independent experiments is presented as mean ± SEM (n=6-8). Statistical analysis: One-way 
ANOVA with Dunnett's multiple comparison test. *p-value < 0.05 in comparison to non-treated control (n.t.). 
 
All PDGF ligands led to an increase in cell invasion into the matrix (Figure 4.6 B, C) with a significant 
effect (p<0.05) observed for PDGF-AB (Figure 4.6 C). This indicates a role of PDGF-AB signaling in the 
invasion properties of lung fibroblasts in a ligand-receptor specific manner. 
 
 PDGF-AB and PDGF-DD enhance PDGF signaling independently of TGFβ 
To study whether TGFβ affects downstream PDGF signaling in phLFs, we treated cells with TGFβ for 48 
h followed by PDGF-AB and PDGF-DD ligand stimulation for 40 min and analyzed the changes in Akt 
phosphorylation via immunoblot. TGFβ alone led to a slight increase in pAkt levels compared to non-treated 
cells, whereas PDGF-AB and PDGF-DD led to a significant increase of pAkt (p<0.05 for PDGF-AB and 
p<0.001 for PDGF-DD). Interestingly, the effect by TGFβ was reversed when additionally stimulated with 
either PDGF-AB or PDGF-DD (Figure 4.7 A-C).  
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Figure 4.7: PDGF-AB and PDGF-DD enhance PDGF signaling independently of TGFβ. (A) Immunoblot analysis of whole 
cell lysates from phLFs treated with 1 ng/ml TGFβ (48 h) followed by stimulation with 10 ng/ml PDGF-AB and PDGF-DD ligands 
(40 min). (B, C) Densitometric quantification of four independent biological replicates (n=4) was used to determine pAkt/Akt ratio. 
Data are shown as mean ± SEM. Statistical analysis: Paired two-tailed t-test. ***p-value < 0.001, *p-value < 0.05. 
 
 PDGF signaling is increased in the absence of PDGFRα  
Furthermore, I wanted to explore if a specific ligand-receptor interaction mainly activates downstream Akt 
signaling in lung fibroblasts. To do so, I performed siRNA-mediated silencing of PDGFRα, PDGFRβ, or 
both receptors in combination and analyzed pAkt in the presence/absence of different PDGF ligands. 
Knockdown efficiency was controlled by FACS, qPCR and immunoblot. We first determined decreased 
receptor levels on the surface after knockdown by FACS analysis to exclude any receptor recycling back to 
the surface which could still lead to further signaling. Receptor-specific knockdown decreased the receptor 
surface levels accordingly (Figure 4.8 A, B). Interestingly, the knockdown of PDGFRα intend to increase 
the number of PDGFRβ positive cells (Figure 4.8 A, B). In addition, qPCR and immunoblot analysis 
revealed an effective knockdown of PDGFRα and PDGFRβ on total mRNA (Figure 4.8 C) and protein 
levels (Figure 4.8 D) after 48 h. 
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Figure 4.8: Knockdown of PDGFRα and PDGFRβ decreases their expression in phLFs. (A) siRNA-mediated knockdown of 
PDGFRα, PDGFRβ, or both (10 nM, 48 h) followed by FACS analysis was used to confirm the surface localization of the receptors 
in phLFs. Shown is a representative dot blot with the isotype control labeled in red and the PDGFRα- and PDGFRβ-positive 
population in blue. (B) Summary of FACS data from three independent biological experiments (n=3) with mean ± SD. (C) qPCR 
and (D) immunoblot analysis of PDGFRα and -β levels from phLFs reversely transfected with 2 or 10 nM of scrambled and 
PDGFRα or PDGFR-β-specific siRNA for 48 h. (C) Data are presented as mean ± SEM from three independent experiments (n=3). 
(D) Shown is one representative blot from three different experiments (n=3). Statistical analysis: Paired two-tailed t-test. *p-value 
< 0.05, **p-value < 0.01, ***p-value < 0.001. scrb = scrambled. 
 
Next, we analyzed the ligand-receptor specific activation and compared this to TGFβ induced effects. As 
expected, PDGF-AB and PDGF-DD stimulation increased pAkt levels in scrambled conditions, which was 
also observed when cells were stimulated with TGFβ (Figure 4.9 A, B). On the other hand, knockdown of 
PDGFRα under basal, scrambled conditions led to a significant increase in pAkt levels, which was not 
observed after PDGFRβ knockdown (Figure 4.9 A). In line with the previous experiment, knockdown of 
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PDGFRα led to a significant increase (p<0.05) in total protein expression of PDGFRβ under basal (wo) as 
well as PDGF-AB, but not PDGF-DD stimulation (Figure 4.9 A, F). This indicates that a potential regulatory 
effect between the two receptors exists in phLFs.  
In the presence of PDGF-AB ligand, PDGFRα-depleted cells displayed a decrease in pAkt levels, whereas 
PDGFRβ-depleted cells showed a decrease in pAkt in the presence of PDGF-DD ligand., These data indicate 
a binding preference of PDGF-AB towards PDGFRα and PDGF-DD towards PDGFRβ receptor (Figure 4.9 
A). Interestingly, knockdown of PDGFRα enhanced pAkt levels when cells had been pre-stimulated with 
TGFβ (Figure 4.9 B, D). 
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Figure 4.9: PDGF ligands enhance PDGF signaling in the absence of PDGFRα. Immunoblot analysis of PDGFRs, pAkt, and 
pSmad3 in whole protein lysates obtained from reversely transfected phLFs with siRNAs against PDGFRα, PDGFRβ, or both for 
48 h and subsequently stimulated with (A) 10 ng/ml of PDGF-AB and PDGF-DD or (B) 1 ng/ml TGFβ for 40 min. One 
representative blot out of six independent biological experiments is shown (n=6). (C-F) Densitometric quantification of pAkt/Akt, 
pSmad3/Smad3 and PDGFRβ/β-actin ratio is shown as mean ± SEM. (C) For statistical analysis of pAkt in non-treated cells (wo), 
six technical replicates of reloaded samples together with six independent biological experiments were used (n=6) and a paired two-
tailed t-test was performed. (D) For statistical analysis of pAkt in the presence of TGFβ, a two-way ANOVA with Bonferroni post-
test was used for six independent biological replicates (n=6). (E, F) For statistical analysis of pSmad3 and PDGFRβ, a paired two-
tailed t-test was used (comparison of single columns). **p-value < 0.01, *p-value < 0.05, ns = not significant. 
 
Additionally, I tested whether downstream PDGF signaling interferes with TGFβ pathway which was 
achieved by analyzing Smad3 phosphorylation (pSmad3), a downstream mediator of canonical TGFβ 
signaling. TGFβ alone enhanced pSmad3 as expected (Figure 4.9 B). Knockdown of PDGFRβ significantly 
decreased pSmad3 without ligand stimulation and in the presence of PDGF-AB (p<0.05) (Figure 4.9 A), 
with a similar trend observed for PDGF-DD stimulation.  
Taken together, my data indicate that TGFβ seems to increase Akt phosphorylation levels in lung fibroblasts 
under basal conditions via a non-canonical TGFβ pathway (Figure 4.9 D). On the other hand, absence of 
PDGFRβ attenuated downstream TGFβ signaling under basal conditions as well as in the presence of ligands 
(Figure 4.9 E) indicating that a potential cross-talk between PDGF and TGFβ signaling exists. 
 
 The activity of tyrosine kinase inhibitor is attenuated in the absence of PDGFRα  
We further wanted to analyze if inhibiting the PDGF receptors for ligand binding would lead to the opposite 
effect of downstream signaling observed. Two different potent tyrosine kinase inhibitors, Imatinib mesylate 
and Nintedanib, were used and the effective concentration first determined by stimulating phLFs in a dose-
dependent manner for 30 min followed by stimulation with PDGF-AB, PDGF-DD, and TGFβ for 40 min. 
Immunoblotting analysis showed that increased concentrations of both inhibitors decreased pAkt levels in 
a PDGF ligand independent way (Figure 4.10 A, B). Importantly, PDGFRα and PDGFRβ expression as 
well as Smad3 phosphorylation remained unaffected in the presence of both inhibitors (Figure 4.10 A-D).  
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Figure 4.10: Imatinib and Nintedanib block PDGF signaling in phLFs. Immunoblot analysis of PDGFRα and -β expression, 
and Akt and Smad3 phosphorylation in the whole protein lysates treated with increased doses of (A) Imatinib and (B) Nintedanib 
for 30 min followed by PDGF-AB and PDGF–DD (10 ng/ml) or TGFβ (1 ng/ml) stimulation for 40 min. Shown is one representative 
blot of three biological replicates (n=3). 
 
Since a stronger effect on Akt phosphorylation was observed when treating cells with Nintedanib compared 
to Imatinib, we continued and further addressed the effect of Nintedanib on PDGF signaling in the presence 
or absence of PDGF receptors. To do so, phLFs were reverse transfected with siRNA against PDGFRα, 
PDGFRβ, or both receptors for 48 h, and afterwards treated with Nintedanib for 30 min followed by PDGF-
AB or PDGF-DD and TGFβ stimulation for 40 min. Basal pAkt (scrambled) levels under normal or PDGF-
AB or TGFβ conditions were decreased by Nintedanib. This effect was, however, less pronounced for 
PDGF-DD (Figure 4.11 A, B). Interestingly, Nintedanib did not attenuate the increase in Akt 
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phosphorylation of PDGFRα-depleted cells (Figure 4.11 A). This indicates that the inhibitory effect of 
Nintedanib is abrogated in the absence of PDGFRα receptor.  
 
 
 
Figure 4.11: The absence of PDGFRα receptor diminishes inhibitory effect of Nintedanib on PDGF signaling. Knockdown 
of PDGFRα, PDGFRβ, or both (10 nM) was performed for 48 h. Cells were treated with 1 µM Nintedanib for 30 min followed by 
(A) PDGF-AB or PDGF-DD (10 ng/ml), and (B) TGFβ (1 ng/ml) stimulation for 40 min. The effect of Nintedanib on PDGF 
signaling in the presence or absence of PDGFRs was analyzed by immunoblot. Shown is one representative blot of six biological 
replicates (n=6). 
 
 Knockdown of PDGFRα together with TGFβ increases myofibroblasts differentiation and 
ECM production  
To investigate the significance of PDGFRα in myofibroblasts differentiation and the effect of Nintedanib, 
we analyzed ECM expression and secretion in phLFs after reverse transfection with siRNA against 
PDGFRα for 48 h, and subsequent stimulation with TGFβ alone or in combination with Nintedanib for 
additional 48 h. Expression changes of αSMA and the selected ECM components fibronectin, collagen I, 
collagen III, and collagen V were analyzed via immunoblot. Protein levels of fibronectin, collagen I, 
collagen V, and αSMA were increased by TGFβ, however, no change was observed for collagen III (Figure 
4.12 A). Interestingly, PDGFRα-depleted cells displayed an increase in αSMA and collagen V expression, 
which was even more prominent in the presence of TGFβ (Figure 4.12 A). Also, increased secretion of 
collagen V by PDGFRα-depleted myofibroblasts was detected in the presence of TGFβ (Figure 4.12 B). 
Next, the impact of Nintedanib on ECM changes in PDGFRα-depleted myofibroblasts was addressed. 
Knockdown of PDGFRα led to a strong increase in αSMA and collagen V expression in the presence of 
Nintedanib. In addition, the inhibitory effect of Nintedanib was lost in the presence of TGFβ for αSMA and 
collagen V, as their expression levels were still detectable. This effect was even more prominent in the 
absence of PDGFRα (Figure 4.12 A). 
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Figure 4.12: Knockdown of PDGFRα enhances αSMA and collagen V expression. (A) Immunoblot analysis of PDGFRα, 
αSMA and selected ECM components in whole cell lysates from phLFs reversely transfected with 10 nM of siPDGFRα for 48 h, 
and in parallel stimulated with TGFβ (1 ng/ml) and Nintedanib (1 µM) for additional 48 h. Shown is one representative Western 
blot of three biological replicates (n=3). (B) Immunoblot analysis of collagen V secretion in cell supernatants obtained from 
PDGFRα-depleted cells treated with or without 1 ng/ml TGFβ for 48 h. Shown are three immunoblots from three different biological 
experiments (n=3).  
 
Taken together, my data indicate that PDGFRα negatively controls TGFβ-mediated myofibroblasts 
transdifferentiation, and enhanced ECM expression and that the inhibitory effect of Nintedanib is lost in the 
presence of TGFβ.  
 
 Identifying the role of CDCP1 in myofibroblast differentiation of human lung fibroblasts 
I next investigated whether CDCP1 controls different profibrotic or antifibrotic properties of lung 
fibroblasts. 
 
 SiRNA-mediated silencing of CDCP1 affects its cell surface and total protein levels in phLFs   
For functional studies, we performed siRNA-mediated silencing of CDCP1 in phLFs and analyzed 
knockdown stability on protein level for 24, 48 and 72 hours by immunoblotting and FACS. The percentage 
of CDCP1-positive cells significantly decreased (p<0.001) after 48 h (Figure 4.13 A, B). Likewise, the MFI 
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values from the knockdown cells significantly declined (p<0.05) for CDCP1 among all cells (Figure 4.13 
B), indicating an efficient surface depletion of CDCP1. Moreover, immunoblot analysis revealed an 
effective CDCP1 protein depletion after 48 h and 72 h. Interestingly, αSMA protein levels increased in 
CDCP1-depleted cells (Figure 4.13 C).  
 
 
 
 
Figure 4.13: Silencing of CDCP1 decreases its cell surface and total protein levels. (A) The percentage of CDCP1-positive cells 
from phLFs incubated for 48 h with scrambled and CDCP1-specific siRNA was determined by FACS. Isotype control is labeled in 
red and CDCP1-positive cells in blue as shown in histogram and dot blot analysis. (B) Changes in the percentage of CDCP1-positive 
cells (left graph) and MFI values (right graph) after CDCP1 silencing for 48 h are presented as a summary of eight independent 
experiments with mean ± SEM (n=8). Statistical analysis: Paired two-tailed t-test. ***p-value < 0.001, *p-value < 0.05. (C) 
Immunoblot analysis of CDCP1 and αSMA levels from whole protein lysates reversely transfected with 2 or 10 nM of scrambled 
and CDCP1-specific siRNA for 24 h, 48 h, and 72 h. Shown is one representative blot from three different experiments (n=3). 
 
 CDCP1 inhibits cell adhesion of phLFs 
CDCP1 plays an essential role in regulating cell adhesion of certain cancer cell lines to the ECM [Deryugina 
et al., 2009; Uekita et al., 2008b]. I therefore wanted to investigate if CDCP1 modulates cell adhesion of 
phLFs, and if this might be dependent on TGFβ. Therefore, phLFs were reversely transfected with siRNA 
against CDCP1, and subsequently treated with TGFβ for 48h. Absence of CDCP1 led to a slight increase in 
the adhesion capacity of lung fibroblasts when compared to control siRNA-transfected cells (Figure 4.14 A, 
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B), and this effect was even more pronounced when siRNA-mediated knockdown of CDCP1 was followed 
by TGFβ stimulation (Figure 4.14 A, B).  
 
 
 
Figure 4.14: CDCP1 silencing negatively impacts cell adhesion of phLFs. (A) PhLFs were reversely transfected with scrambled 
(siScr) or CDCP1 siRNA (siCDCP1) for 48 h followed by incubation with or without (-/+) 1 ng/ml TGFβ for 48 h. Thereafter, cells 
were placed in a 48-well plate and allowed to attach for 10 min. Attached cells were subsequently fixed with 4 % PFA, stained with 
DAPI (green) and Phalloidin (red), and a confocal LSM microscope was used to scan and thus image each well. Shown are 
representative images of one replicate out of four technical replicates from five different biological experiments (n=5). Scale bar: 
10 µm. (B) Summary of cell adhesion data from (A) presented as mean ± SEM. Statistical analysis: One-way ANOVA with 
Bonferroni's Multiple Comparison Test. **p-value < 0.01. 
 
 Absence of CDCP1 enhances the expression of αSMA and ECM proteins 
In section 4.4.1 we observed changes in αSMA levels after knocking down CDCP1. We next wanted to 
investigate, if CDCP1 takes part in myofibroblast differentiation, a process known to be mainly activated 
by TGFβ, and characterized by an αSMA expressing and increased ECM secreting phenotype. We therefore 
performed siRNA-mediated silencing of CDCP1 followed by cell stimulation with TGFβ for 48 h. 
Immunoblot was used to monitor the expression changes of αSMA and the ECM proteins fibronectin, 
collagen type I, III and V. TGFβ alone led to an increase in αSMA, collagen, and fibronectin protein levels 
(Figure 4.15 A, B). Interestingly, the knockdown of CDCP1 alone significantly enhanced (p<0.01) the 
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expression of collagen V. This effect was even more prominent for collagen V and collagen III when cells 
were additionally stimulated with TGFβ (Figure 4.15 A, B). 
Also, CDCP1 enhanced αSMA protein expression independently of TGFβ as shown via immunoblotting 
(Figure 4.15 A, B), and immunofluorescence stainings of methanol-fixed phLFs monolayers (Figure 4.15 
C). Moreover, immunofluorescence stainings of healthy and IPF tissue sections revealed that αSMA-
positive interstitial myofibroblasts located in fibroblastic foci of IPF lung sections displayed a low 
expression of CDCP1 (Figure 4.15 D, lower panel), whereas non-differentiated interstitial lung fibroblasts 
in sections of healthy lungs were highly CDCP1-positive, and clearly αSMA-negative (Figure 4.15 D, upper 
panel).  
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Figure 4.15: CDCP1-depleted lung fibroblasts exhibit increased αSMA and ECM expression. (A) Cells were transfected with 
control scrambled (-) or CDCP1-specific siRNA (+), and subsequently stimulated with 1 ng/ml TGFβ for 48 h. The changes in 
protein expression of CDCP1, αSMA, collagens, and fibronectin in total cell lysates were monitored via immunoblot. Shown is one 
representative immunoblot from five-ten independent biological experiments (n=5-10). (B) Densitometric quantification from (A) 
presented as mean ± SEM. Statistical analysis: Paired two-tailed t-test for a comparison of single columns. ***p-value < 0.001, 
**p-value < 0.01, *p-value < 0.05. (C) Representative stainings of methanol-fixed phLFs monolayers, which were reversely 
transfected with scrambled (scr) and CDCP1-specific siRNAs (siCDCP1), and treated in the presence or absence of 1 ng/ml TGFβ 
for 48 h. Images were acquired by confocal microscopy scanning each well (8x8 tiles scanning area). Nuclei were counterstained 
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with DAPI (white). Representative images from three independent experiments are shown (n=3). Scale bar: 1000 µm. (D) 
Immunofluorescent co-stainings of CDCP1 (red, yellow arrows) and αSMA (green) in healthy (upper panel) and IPF (lower panel) 
paraffin tissues sections. Nuclei were counterstained with DAPI (blue). Shown is one representative section from four different 
donors (n=4) and four different IPF patients (n=4). Scale bar: 50 µm. EF = elastic fibers, MyF = myofibroblasts. 
 
 CDCP1 inhibits canonical TGFβ signaling in lung fibroblasts 
Moreover, I tested whether CDCP1 impacts downstream TGFβ signaling in phLFs. Thus, siRNA-mediated 
knockdown of CDCP1 for 48 h was performed followed by cell treatment with TGFβ for 1 h, 26 h, and 48 
h. Changes in Smad3 phosphorylation were analyzed via immunoblot. TGFβ alone increased Smad3 
phosphorylation levels as expected (Figure 4.16 A-D). Surprisingly, CDCP1-depleted cells exhibited an 
even stronger increase in Smad3 phosphorylation (p<0.05) in the presence of TGFβ (Figure 4.16 D).  
To further corroborate our data, phLFs were stimulated as described above and subsequently a luciferase 
reporter assay was performed using the Smad3-reporter pGL3-CAGA(9)-luc plasmid [Dennler et al., 1998] 
and a control pGL-4 plasmid. The knockdown of CDCP1 significantly enhanced (p<0.05) the TGFβ-
mediated Smad3 promoter activity after 26 h and 48 h (Figure 4.16 E, F).  
 
 
 
Figure 4.16: Absence of CDCP1 enhances TGFβ-mediated Smad3 phosphorylation in phLFs. Reverse transfection of phLFs 
with either control scrambled or CDCP1-specific siRNA was performed for 48 h, followed by cells stimulation with or without 1 
ng/ml TGFβ for (A) 1 h, (B) 26 h, and (C) 48 h. Whole cell lysates were immunoblotted for CDCP1, phosphorylated and total 
Smad3, and αSMA. Shown is one representative immunoblot out of six performed experiments (n=6). (D) Densitometric 
quantification of pSmad3/Smad3 ratio from (A-C) presented as mean ± SEM. Statistical analysis: One sample t-test. *p-value < 
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0.05 (E, F) Lung fibroblasts were first reversely transfected with siRNA against CDCP1 and 24h after the transfection, Smad 
signaling luciferase reporter or control construct were transfected to cells followed by TGFβ stimulation (1 ng/ml) for 26 h or 48 h. 
Luciferase activity was measured and data compared between TGFβ and siCDCP1+TGFβ treatments. All measurements were 
performed in four technical replicates per each condition. Data are presented as a summary of three independent experiments (n=3) 
with mean ± SEM. Statistical analysis: Paired two-tailed t-test. *p-value < 0.05. 
 
Taken together, my data suggest that CDCP1 negatively regulates cell adhesion, ECM expression, and 
myofibroblasts transdifferentiation, by affecting downstream TGFβ signaling in human lung fibroblasts.  
 
 TGFβ regulates CDCP1 expression via non-canonical TGFβ signaling pathway 
Finally, I wanted to explore the molecular mechanism by which TGFβ regulates CDCP1 expression in lung 
fibroblasts. At first, mediators of canonical TGFβ pathway were tested by treating phLFs with SB431542, 
a specific inhibitor targeting Alk5 receptor, or Sis3, a specific inhibitor of Smad3 phosphorylation, together 
with TGFβ for 48 h. Changes in CDCP1 expression were monitored via immunoblot. The expression of 
CDCP1 remained decreased by TGFβ in cells treated with SB431542 or Sis3 (Figure 4.17 A, B). Thus, I 
next analyzed whether TGFβ decreases CDCP1 expression via non-canonical TGFβ signaling. To do so, I 
stimulated phLFs with inhibitors targeting pErk1/2 (UO126), PAR1, PAR2, and a broad spectrum of matrix 
metalloproteases, including MMP1-3, MMP7-9, MMP12, MMP14, and MMP26 (GM6001) in parallel with 
TGFβ for 48 h (Figure 4.17 C-F). Surprisingly, CDCP1 protein levels remained still decreased indicating 
that TGFβ regulates CDCP1 expression via another, unknown mechanism. 
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Figure 4.17: TGFβ attenuates CDCP1 expression via non-canonical signaling. Primary human lung fibroblasts were incubated 
with 1 ng/ml TGFβ together with specific inhibitors or antagonists targeting (A) Alk5 receptor, (B) phosphorylated Smad3, (C) 
phosphorylated Erk1/2, (D) PAR1 receptor, (E) PAR2 receptor, and (F) a broad range of MMPs every 24 h for a total 48 h. The 
whole protein lysates were immunoblotted for CDCP1, αSMA, phosphorylated and total Smad3, phosphorylated and total Erk1/2. 
Equal loading was confirmed by probing each membrane for β-actin. Shown are representative blots out of three independent 
experiments (n=3). Non-treated cells were marked as ''wo''. 
 
 TGFβ decreases CDCP1 expression levels via ubiquitin-independent proteasomal 
degradation 
Autophagy and the ubiquitin-proteasome pathway are well-known as the major protein degradation systems 
in eukaryotic cells [Lilienbaum, 2013]. Hence, I speculated that TGFβ decreases CDCP1 expression in 
phLFs via one of these mechanisms.  
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First, I tested whether TGFβ enhances CDCP1 downregulation via autophagy. Therefore, phLFs were 
treated with Bafilomycin, an inhibitor of the late phase of autophagy together with TGFβ for 48 h and 
expression changes of CDCP1 upon treatment analyzed via immunoblot. CDCP1 expression levels, 
however retained decreased in the presence of Bafilomycin together with TGFβ (Figure 4.18 A). 
Additionally, Smad3 phosphorylation levels remained unchanged between non-stimulated and 
Bafilomycin-stimulated cells in the presence of TGFβ, indicating that TGFβ does not mediate CDCP1 
degradation via autophagy (Figure 4.18 A).  
I next tested whether TGFβ mediates downregulation of CDCP1 expression by proteasomal degradation. 
PhLFs were treated with the proteasome inhibitor Bortezomib in a concentration-dependent manner (1-10 
nM) together with TGFβ for 48 h and changes in CDCP1 expression upon treatment monitored via 
immunoblot (Figure 4.18 B). Ten nM of Bortezomib prevented downregulation of CDCP1 expression in 
the presence of TGFβ (Figure 4.18 C) indicating that TGFβ potentially drives CDCP1 degradation in the 
proteasome. For proteasomal degradation proteins are tagged with ubiquitin molecules. This polyubiquitin 
chain functions as a signal and gets bound by the proteasome. Thus, I next tested whether CDCP1 is more 
ubiquitinated in the presence of TGFβ. To do so, pulldown of CDCP1 from the whole protein lysates treated 
with 10 nM of Bortezomib together with TGFβ for 48 h was performed and ubiquitination status of CDCP1 
addressed via immunoblot (Figure 4.18 D). Immunoblotting indicated a high enrichment of CDCP1 via 
immunoprecipitation, however no ubiquitination of CDCP1 was detected upon treatment (Figure 4.18 D). 
Interestingly, Bortezomib treatment in the presence of TGFβ restored CDCP1 expression already on the 
mRNA level (Figure 4.18 E). Of note, 10 nM of Bortezomib also counteracted TGFβ-mediated increase of 
αSMA protein (Figure 4.18 C) and gene (Figure 4.18 E) expression. We conclude that CDCP1 degradation 
by TGFβ does not occur due to protein ubiquitination but involves a more complex, and yet unknown 
mechanism. 
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Figure 4.18: TGFβ potentially attenuates CDCP1 expression via a complex proteasomal degradation. Immunoblot of entire 
protein lysates from phLFs treated for 48 h with 1 ng/ml TGFβ together with increasing concentrations (wo, DMSO, 1-10 nM) of 
(A) Bafilomycin and (B) Bortezomib. (A, B) Membranes were probed for CDCP1, αSMA, phosphorylated Smad3, and Smad3 as 
indicated. (A) LC3B was used as a positive control of the effective autophagy inhibition. Shown is one representative immunoblot 
out of three performed experiments (n=3). (B) UbiK48 was used as a positive control of the effective proteasome inhibition. Shown 
is one representative blot out of six independent experiments (n=6). Equal protein loading in (A, B) was confirmed by probing 
membranes for β-actin. (C) Densitometric quantification of CDCP1 and αSMA total protein levels from (B) with data presented as 
mean ± SEM. (D) PhLFs were stimulated in the presence or absence of TGFβ together with 10 nM Bz for 48 h and direct interaction 
of CDCP1 and ubiquitin in immunoprecipitants from the whole protein lysates analyzed via immunoblot. One representative blot 
out of three independent experiments is shown (n=3). (E) qRT-PCR analysis of CDCP1 and αSMA gene expression from phLFs 
treated with TGFβ together with 10 nM Bz for 48 h. HPRT was used as a housekeeping gene. Data are depicted as mean ± SEM 
from three independent experiments (n=3). Statistical analysis: One-way ANOVA with Bonferroni's Multiple Comparison Test. 
***p-value < 0.001, **p-value < 0.01, *p-value < 0.1, ns = non-significant. Bz = Bortezomib. 
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5 DISCUSSION 
Myofibroblasts are characterized as essential effector cells in IPF, since they belong to the main ECM 
producing cell types, highly proliferating and by this maintaining the fibrotic pathological state. The 
cytokine TGFβ is the main effector driving transdifferentiaton of cells into this active αSMA expressing cell 
phenotype. Myofibroblasts are specified by intracellular marker expression of collagen, fibronectin, or 
desmin. The surface proteome, however, has only little been characterized. In an unbiased surface proteome 
analysis of primary human lung fibroblasts, our research group identified that the surface proteome of 
primary human lung fibroblasts is intensively regulated by TGFβ. Two of the top downregulated candidates, 
PDGFRα and CDCCP1, have been in the focus of my thesis to characterize in detail the functional outcome 
of this regulation in the context of lung fibrosis.  
We first confirmed protein expression and localization on the surface of fibroblasts in general and its 
downregulation by TGFβ. Further, my work described for the first time a potential PDGFRα/TGFβ cross-
talk in lung fibroblasts. PDGF-AB predominantly activated PDGFRα, whereas PDGF-DD activated 
PDGFRβ receptor. Interestingly, PDGFRα-depleted cells displayed an increase in PDGFRβ expression 
indicating a compensatory effect between the two receptors. Further, the invasion capacity of lung 
fibroblasts is regulated by PDGF-AB ligand in a PDGFRα-dependent manner. Importantly, tyrosine kinase 
inhibitor Nintedanib decreased TGFβ-induced collagen V and αSMA expression, but surprisingly this effect 
was largely attenuated in the absence of PDGFRα. Finally, I could show that Nintedanib also enhanced total 
collagen secretion in PDGFRα-depleted cells.  
CDCP1 is exclusively localized on the surface of phLFs. Mechanistic studies revealed that TGFβ decreases 
CDCP1 expression via an ubiquitin-independent pathway, but not via Smad or MAPK signaling. I also 
showed for the very first time that CDCP1 impacts downstream TGFβ signaling as demonstrated by 
increased Smad3 phosphorylation in CDCP1-depleted cells treated with TGFβ and which in consequence 
enhances αSMA, collagen III and collagen V total protein expression. Moreover, I showed that loss of 
CDCP1 positively impacts TGFβ-mediated cell adhesion of lung fibroblasts. 
 
 Fibroblasts cell-surface proteome in response to profibrotic TGFβ 
To date, characterization of the fibroblasts surface proteome under basal as well as growth factor stimulation 
is not clearly assessed despite its essential importance in understanding how activated fibroblasts contribute 
to pathological processes in IPF [Laurent et al., 2008; Tschumperlin and Drazen, 2006; Kendall and Feghali-
Bostwick, 2014]. TGFβ is one of the most intensively studied profibrotic growth factors driving fibroblasts 
to myofibroblasts differentiation and maintaining this phenotype in IPF [Kendall and Feghali-Bostwick, 
2014; Serini and Gabbiani, 1999]. Therefore, our research group initially investigated changes in the surface 
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proteome of primary human lung fibroblasts under normal and TGFβ-stimulated conditions [Heinzelmann 
et al., 2016].   
There is an emerging need to uncover specific myofibroblast surface markers in disease [Hinz et al., 2007b; 
Baum and Duffy, 2011]. Surface proteins represent easy accessible targets for specific pharmacological 
compounds compared to intracellular molecules [Hinz et al., 2007b; Ivarsson et al., 1998]. To date, there 
are only few studies characterizing fibroblasts surface proteome under basal and growth factor stimulation. 
Recently, Slany and colleagues performed a proteomics analysis of IL-1β-stimulated control tumor-free and 
tumor-associated primary human fibroblasts isolated from skin, lungs, and bone marrow using LC-MS/MS 
[Slany et al., 2014]. Within the intracellular proteome fraction (cytoplasm, nuclear extract, and secretome) 
of tumor-associated fibroblasts, they identified IGF-II, PAI-1, and PLOD2 among the top upregulated 
proteins by IL-1β, and further proposed that their upregulation may contribute to tumor development during 
early stages of chronic inflammation. Another study by Predic and co-authors investigated the changes of 
human lung fibroblasts' proteome in the presence and absence of endothelin-1, identifying Rab3a, Rab14, 
and Sox5 among its main targets [Predic et al., 2002]. Moreover, Pilling and colleagues aimed to analyze 
expression profiles of selected markers via immunostainings to specifically discriminate between human 
monocytes, macrophages, fibrocytes, and fibroblasts [Pilling et al., 2009]. Study by Halfon and colleagues 
aimed to uncover new gene and surface protein markers which are differentially expressed between 
mesenchymal stem cells (MSCs) and dermal fibroblasts which would be beneficial for assessing the purity 
of MSCs expanded in vitro [Halfon et al., 2011]. Surface marker profiling of fibroblasts have been 
previously described by Walmsley and colleagues [Walmsley et al., 2015]. Here, authors showed that 
freshly isolated, uncultured dermal fibroblasts showed different surface marker profile compared to cultured 
fibroblasts [Walmsley et al., 2015]. Nevertheless, the expression analysis of lung fibroblast surface 
proteome remains rare, as specific fibroblast surface markers have not been identified to date. Moreover, 
most studies were performed in mouse, and thus it is questionable if all data can be transferred to human 
system. Further studies are also required to uncover which of those identified markers play a role in disease. 
 
 TGFβ effect on PDGF receptor expression in phLFs 
PDGFRα is a tyrosine kinase receptor and its expression has been described in different cell types including 
fibroblasts, fibrocytes and platelets [Vassbotn et al., 1994; Heldin and Westermark, 1999; Aono et al., 2014]. 
Importantly, the overall expression levels of PDGF receptors are not constant in the cells, but rather vary in 
response to various stimuli. Here I showed that profibrotic cytokine TFGβ decreases cell surface and total 
protein expression levels of PDGFRα, whereas PDGFRβ surface and total protein levels increased upon the 
treatment in primary human lung fibroblasts (Figure 4.1 and Figure 4.2). Our data confirm previous data by 
Bonner and colleagues, who also reported downregulation of PDGFRα gene expression by TGFβ in human 
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lung fibroblasts [Bonner et al., 1995]. A decrease in PDGFRα gene expression by TGFβ has also been 
described in 3T3 mouse fibroblasts, in neonatal human foreskin fibroblasts, and in mesothelial cells 
[Langerak et al., 1996; Gronwald et al., 1989; Paulsson et al., 1993]. These studies, however, have 
predominantly focused on changes in PDGFRα expression on the transcript rather than protein levels. In 
contrast, PDGFRα gene and protein expression has been shown to be upregulated by TGFβ in scleroderma 
fibroblasts [Yamakage et al., 1992]. On the other hand, it has been described in the experimental model of 
liver fibrosis that PDGFRβ expression levels are highly increased by TGFβ [Bissell et al., 1995]. Likewise, 
we observed an increase in PDGFRβ surface and total protein expression by TGFβ (Figure 4.2 and Figure 
4.9 B), and importantly, an upregulation of PDGFRβ after knockdown of PDGFRα (Figure 4.8 and Figure 
4.9).  
 
 PDGF ligand-receptor binding affinities in phLFs 
PDGF signaling plays a critical role in various cellular responses of fibroblasts, including cell proliferation, 
migration, and the ECM synthesis, which are all essential for processes of normal wound healing [Alvarez 
et al., 2006]. However, aberrant PDGF signaling has been linked to several lung diseases, including lung 
fibrosis [Bonner, 2004a]. PDGF signaling is activated by binding of specific PDGF ligands to their PDGF 
receptors. Whether a specific ligand-receptor interaction impacts pathological mechanisms in disease has 
not been clarified yet in the field. [Donovan et al., 2013]. We analyzed ligand-binding affinities of PDGF-
AB and PDGF-DD to PDGF receptors in human lung fibroblasts and found that PDGF-AB binds with the 
highest affinity to PDGFRα whereas PDGF-DD binds to PDGFRβ (Figure 4.9 A). 
The binding affinities of PDGF ligands towards their receptors have been controversially discussed in the 
literature [Donovan et al., 2013; Bergsten et al., 2001; Heldin et al., 1988]. In line with our findings,  it has 
been previously shown in in vitro studies that PDGF-AB ligand binds PDGFRα, whereas PDGF-DD showed 
higher binding affinities exclusively towards PDGFRβ receptor [Heldin et al., 2002; Chen et al., 2013; 
Kanakaraj et al., 1991]. Donovan and colleagues compared PDGF ligand-receptor-specific binding patterns 
in dermal versus lung fibroblasts by analyzing phosphorylation status of PDGFRα and PDGFRβ receptors 
in the presence of single PDGF ligands [Donovan et al., 2013]. Interestingly, they observed that all tested 
PDGF ligands, including PDGF-DD increased phosphorylation of PDGFRα receptor in human lung 
fibroblasts [Donovan et al., 2013], which is in contrast with our findings (Figure 4.9 A). Little information 
exists regarding binding affinities of PDGF-AB and PDGF-DD ligands to PDGF receptors in vivo [Andrae 
et al., 2008]. Here, PDGF-DD have been recently described to bind PDGFRαβ receptor, but its functional 
significance remains the subject of ongoing investigations [Heldin and Lennartsson, 2013]. PDGF-AB has 
not been investigated in this context to date.    
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 PDGF signaling in human lung fibroblasts 
It has been thought for a long time that growth factors, including PDGFs transduce signals solely via their 
specific receptors. Generally, PDGFs signal intracellularly via two different and independent signaling 
pathways, namely MAPK cascade via phosphorylation of RAF, MEK, and ERK [Monje et al., 2003] and 
on the other hand PI3K pathway via phosphorylation of Akt and mTOR [Razmara et al., 2013]. 
Nevertheless, recent studies indicate that PDGF signaling extensively cross-talks with other signaling 
pathways, such as EGFR, Wnt or AngII signaling [Mendelson et al., 2010; Miller et al., 2012; Linseman et 
al., 1995; Heeneman et al., 2000].  
In this study I demonstrated that PDGF signaling cross-talks with TGFβ signaling, as shown by increased 
phosphorylation of Akt when cells were treated in the combination with TGFβ and PDGF ligands (Figure 
4.7 and 4.9) and, on the other hand, decreased Smad3 phosphorylation in the absence of PDGFRβ (Figure 
4.9 A, E). To my knowledge, this has not been previously reported in primary human lung fibroblasts or in 
lung fibrosis. Interestingly, a cross-talk between PDGFRβ and TGFβ signaling have recently been described 
in primary dermal fibroblasts [Porsch et al., 2014]. Here, authors demonstrated that PDGFRβ and TGFβRI 
receptors physically interact via either the extracellular or transmembrane domain of PDGFRβ receptor. 
Additionally, they showed that PDGF-BB induces TGFβ signaling as shown by increased Smad2 
phosphorylation and expression of TGFβ responsive gene PAI-1, however the exact mechanism behind 
PDGF-BB-induced TGFβ signaling remains unclear [Porsch et al., 2014]. Lastly, their study demonstrated 
that TGFβ controls PDGF-BB-mediated cell migration as treatment of primary human dermal fibroblasts 
with GW6604, a TGFβ kinase inhibitor, led to a decrease in wound closure compared to PDGF-BB-treated 
cells [Porsch et al., 2014]. Interestingly, Murray-Rust and colleagues had speculated that PDGF-BB might 
directly bind to the TGFβ receptor as PDGFs and TGFβ shared topological similarities [Murray-Rust et al., 
1993]. Liu and co-workers studied the role of PDGFRα and PDGFRβ in TGFβ signaling of primary human 
hepatic stellate cells [Liu et al., 2014]. They observed that knockdown of PDGFRα, but not PDGFRβ, 
attenuates TGFβ-mediated Smad2 phosphorylation as well as accumulation of Smad2 in the cell nucleus of 
hepatic stellate cells. We, in contrast, found that knockdown of PDGFRβ led to a decrease in Smad3 
phosphorylation under basal as well as PDGF-AB and -DD stimulation in human lung fibroblasts (Figure 
4.9 A, E).  
 
 PDGF signaling in cell invasion 
PDGF signaling regulates various cellular processes, including cell proliferation, and migration via specific 
receptor-ligand interactions [Kimani et al., 2009; Noskovičová et al., 2015; Boström et al., 2002]. However, 
the invasion potential of fibroblasts due to ligand dependent signaling has not been characterized to date. 
Here, I showed that PDGF-AB increases cell invasion properties of primary human lung fibroblasts in a 
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PDGFRα-dependent manner (Figure 4.6). To my knowledge, the role of PDGF signaling in modulating 
invasion properties of primary human lung fibroblasts has not been investigated to date. Although, it has 
been recently published in our laboratory, that PDGF-BB stimulation enhances the invasion properties of 
fibroblasts, the study was performed with mouse lung fibroblasts [Oehrle et al., 2015]. There is an increased 
evidence that PDGF signaling plays a role in invasion and metastasis of cancer cells [Andrae et al., 2008]. 
Neri and colleagues reported that cancer cells undergoing epithelial-to-mesenchymal transition (EMT) 
activate subpopulation of cancer-associated fibroblasts (CAFs) which possess abilities to remodel collagen 
matrix and thus facilitate cancer cell invasion via PDGF-BB/PDGFRβ axis [Neri et al., 2016]. 
 
 Targeting PDGF signaling in IPF 
Pharmacological treatment options of IPF patients are still very limited to date. In 2014 Nintedanib 
(BIBF1120) was approved by the US Food and Drug Administration (FDA) for IPF therapy [Richeldi, 2014; 
Spagnolo et al., 2015]. Nintedanib inhibits kinase activity of PDGF, VEGF, and FGF receptors by occupying 
their intracellular ATP-binding sites which in turn results in a blockage of receptors' autophosphorylation 
and thus downstream signaling [Wollin et al., 2015]. Imatinib mesylate is another tyrosine kinase inhibitor 
which blocks the activity of PDGFRα and PDGFRβ receptors, discoidin domain receptors (DDR1 and 
DDR2), c-kit, and c-Abl [Day et al., 2008; Buchdunger et al., 2002] in a similar mechanism as Nintedanib 
[Radford, 2002]. In my studies I analyzed the inhibitory effect of tyrosine kinase inhibitors Imatinib and 
Nintedanib on downstream PDGF signaling in primary lung fibroblasts and observed that Akt 
phosphorylation levels were decreased by both drugs in a concentration dependent-manner (Figure 4.10). 
Thereby, all tested doses used were in the physiological range and consistent with those previously 
published [Knüppel et al., 2017; Hostettler et al., 2014; Dewar et al., 2003; Zhang et al., 2003]. Wollin and 
colleagues showed that Nintedanib inhibited downstream PDGF signaling as shown by decreased 
phosphorylarion of Akt and Erk in mouse lung tissues [Wollin et al., 2014] which is consistent with my 
observations in primary human lung fibroblasts (Figure 4.10 and Figure 4.11). Additionally, they showed 
that Nintedanib blocked PDGF-BB-mediated autophosphorylation of PDGFRα and PDGFRβ in primary 
human lung fibroblasts isolated from donor lungs as well as in mouse lung tissue [Wollin et al., 2014]. 
Interestingly, in my study Nintedanib did not block PDGFRβ-mediated signaling in the absence of PDGFRα 
since phosphorylation levels of Akt still remained increased (Figure 4.11 A) indicating that the inhibitory 
effect of Nintedanib on PDGF signaling is attenuated in the absence of PDGFRα.  
We also observed that PDGFRα-depleted cells displayed an increase in the expression levels of collagen V 
and αSMA (Figure 4.12 A), and this effect was even more prominent in the presence of TGFβ. The role of 
PDGFRα in myofibroblasts differentiation has been previously investigated in systemic sclerosis [Liu et al., 
2013]. Here, authors showed that siRNA-mediated depletion of PDGFRα led to a downregulation of αSMA 
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expression on mRNA and protein levels in dermal fibroblasts. Additionally, we observed that PDGFRα 
knockdown enhanced the effect of TGFβ on collagen V secretion in primary human lung fibroblasts (Figure 
4.12 B). Interestingly, Nintedanib did not diminish TGFβ-mediated increase of collagen V and αSMA 
expression (Figure 4.12 A). The effect of Nintedanib alone on ECM expression has been previously 
investigated by Wollin and colleagues who showed that Nintedanib reduced collagen I expression in primary 
human lung fibroblasts treated with TGFβ [Wollin et al., 2014]. Furthermore, they observed that Nintedanib 
administration significantly decreased fibrosis and total lung collagen levels in the lungs of bleomycin-
treated mice [Wollin et al., 2014]. In line with this study, Rangarajan and colleagues reported a decline in 
collagen I expression levels in primary human IPF lung fibroblasts treated with Nintedanib in a dose- and 
time-dependent manner [Rangarajan et al., 2016]. It has also been shown that collagens, including collagen 
V can interact with PDGF ligands and thus regulate cellular functions [Somasundaram and Schuppan, 1996; 
Scotton and Chambers, 2007]. Similarly, several studies reported that Nintedanib blocked TGFβ-mediated 
myofibroblasts transdifferention of primary human lung fibroblasts from IPF patients as determined by 
decreased expression of αSMA on mRNA and protein levels [Wollin et al., 2014; Lehtonen et al., 2016]. I 
could not confirm these data. Our observations might indicate a potential role of PDGF signaling via 
receptor α in modulating Nintedanib function. In summary, my data indicate that TGFβ alters the effect of 
tyrosine kinase inhibitor Nintedanib probably via the potential cross-talk between PDGF and TGFβ 
signaling which in the end may lead to the observed activation of fibroblasts and thus enhanced ECM 
expression.  
 
 TGFβ-mediated expression changes of CDCP1 in phLFs 
CDCP1 is a cell surface glycoprotein which expression has been extensively characterized in epithelial cells 
of various organs including the lung, colon, pancreas, and breast [Orchard-Webb et al., 2014; Miyazawa et 
al., 2010; Ikeda et al., 2009; Wright et al., 2016]. My data showed for the first time CDCP1 expression and 
surface localization in primary human lung fibroblasts (Figure 4.3). Hooper and colleagues reported that 
microvascular endothelial cells and dermal fibroblasts do not express CDCP1 [Hooper et al., 2003]. 
Additionally, CDCP1 was also found to be expressed on the surface of hematopoietic progenitor cells, liver 
hepatocytes and primary cultures of dermal keratinocytes [Brown et al., 2004a; Siva et al., 2008; Buhring 
et al., 2004; Takeda et al., 2010]. 
Little information exists about regulators of CDCP1 expression. Here, I showed that CDCP1 mRNA and 
protein expression levels are significantly downregulated by TGFβ in primary human lung fibroblasts 
(Figure 4.4). The impact of TGFβ on CDCP1 expression has been previously investigated by Miura and 
colleagues, but their study was performed with human pancreatic cell lines [Miura et al., 2014]. In contrast 
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with this study they showed an upregulation of CDCP1 mRNA and protein expression by TGFβ, and also 
BMP4 and HGF, indicating a cell type and organ specific regulation of CDCP1 by TGFβ.  
 
 TGFβ potentially drives an ubiquitin-independent degradation of CDCP1 in the proteasome 
TGFβ can exert its cellular functions via the classical Smad signaling pathway, or via different non-
canonical signaling, including Ras-Erk-MAPK, JNK/p38, and PI3K/Akt pathway [Massagué, 2012; 
Mulder, 2000; Mu et al., 2012]. My data showed that TGFβ regulates CDCP1 expression neither via non-
Smad3 nor the non-canonical MAPK pathway, but potentially reduces CDCP1 levels via proteasomal 
degradation of CDCP1 (Figure 4.17 and 4.18). TGFβ has recently been described to mediate an ubiquitin-
proteasome degradation of parathyroid hormone-related protein (PTHrP) in human hepatocarcinoma cell 
lines [Li et al., 2015]. Moreover, Petrel and Brueggemeier showed that the proteasome inhibitor MG132 
blocked TGFβ-mediated decrease in the estrogen receptor alpha (ERα) in several breast cancer cell lines 
[Petrel and Brueggemeier, 2003]. We observed a clear accumulation of CDCP1 when blocking proteasomal 
entrance with Bortezomib. Interestingly, we did not detect any enriched ubiquitination of CDCP1, neither 
in the presence of TGFβ1 alone nor in the presence of Bortezomib (Figure 4.18 D). Proteins subjected for 
proteasomal degradation must undergo prior ubiquitin modification, which can be mediated via addition of 
one (monoubiquitination) or several ubiquitins (polyubiquitination) [Farràs et al., 2005; Glickman and 
Raveh, 2005; Glickman and Ciechanover, 2002]. Therefore, if CDCP1 is ubiquitinated only with few 
ubiquitins, the antibody used might not detect the ubiquitinated protein complex. Moreover, it has also been 
suggested that the proteasomal degradation is not always followed by a detectable increase in the 
ubiquitination of the substrate. This might be due to various reasons, including the fact that the pool of free 
ubiquitins in the cell is limited and only the kinetically favored proteins can undergo increased 
ubiquitination [Jariel-Encontre et al., 2008]. Another possible explanation might be that TGFβ1-mediated 
proteasomal degradation of CDCP1 occurs via an ubiquitin-independent mechanism, as it has been 
described before for tumor suppressor p53 [Asher et al., 2005]. Here, authors showed that ubiquitin-
independent degradation of p53 in the proteasome is mediated by the enzymatic activity of NAD(P)H-
quinone oxidoreducates (NQO-1). Moreover, Kong and colleagues reported that the histone deacetylase 
(HDAC) TSA moderates HIF-1α degradation via the ubiquitin-independent proteasome pathway in RCC4 
cells as they showed lack of HIF-1α ubiquitination in the presence of the proteasome inhibitor MG132. 
Instead, they suggested that hyperacetylation of HIF-1α chaperon protein HSP-70 due to loss of HDAC-6 
results in accumulation and further degradation of instable HIF-1α/HSP70 complex in the proteasome [Kong 
et al., 2006].  
We also observed that mRNA levels of CDCP1 decrease upon Bortezomib stimulation in the presence or 
absence of TGFβ (Figure 4.18 E). Our data thus indicate that decreased CDCP1 expression by TGFβ is 
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restored already on transcription level indicating a more complex mechanism involving different cellular 
levels. Another possible explanation of this effect might be that in the presence of TGFβ, a positive regulator 
of CDCP1 transcription is subjected for an ubiquitin-dependent proteasomal degradation. A similar pattern 
has been shown for TAL1/SLC, a basic helix-loop-helix transcription factor critical for hematopoietic and 
endothelial cell differentiation [Terme et al., 2009]. Here, TGFβ induced a polyubiquitination, and thus 
proteasome-mediated degradation of TAL1/SCL in HeLa and Jurkat cells, leading to a downregulation of 
TAL1/SLC expression in leukemic cells. To date, limited information exists about CDCP1's transcriptional 
regulation. Not long ago, Emerling and colleagues identified HIF-2α as a novel regulator of CDCP1 
transcription in MRC10A cells [Emerling et al., 2013]. However, it has been reported that HIF-2α 
expression is upregulated by TGFβ in human mesangial 441 cells [Hanna et al., 2013] suggesting that 
another transcriptional regulator may be involved in this process.  
 
 CDCP1 as a negative regulator of TGFβ signaling 
Cross-talk between TGFβ pathway and other signaling pathways has been intensively studied during the 
last decade [Vert and Chory, 2011; Guo and Wang, 2009]. My data indicate that CDCP1 interferes with 
TGFβ signaling since CDCP-depleted primary human lung fibroblasts displayed an increase in Smad3 
phosphorylation in the presence of TGFβ (Figure 4.16). TGFβ and its activated downstream signaling is one 
of the main drivers of fibroblasts to myofibroblasts transdifferentiation in IPF. One of the main phenotypical 
features of activated myofibroblasts is increased expression of αSMA [Hinz, 2016] primarily regulated via 
TGFβ's downstream Smad2/3 signaling [Feng and Derynck, 2005; Massagué et al., 2005]. I observed an 
increase of αSMA in the absence of CDCP1 (Figure 4.15 A, B), and further showed that αSMA-positive 
myofibroblasts accumulating in fibroblastic foci of IPF lungs, display a hardly detectable CDCP1 
expression, whereas interstitial lung fibroblasts within the healthy lung were clearly CDCP1-positive with 
no detectable αSMA expression (Figure 4.15 D). Limited information exists about CDCP1 signaling in 
general. Ligands binding CDCP1 are largely unknown to date [Wortmann et al., 2009]. To our knowledge, 
a possible cross-talk to TGFβ signaling has not been described yet. Further studies identifying mediators of 
CDCP1 signaling will provide a closer insight how CDCP1 interferes with TGFβ signaling.  
I also demonstrated that CDCP1 inhibits TGFβ-mediated cell adhesion of primary human lung fibroblasts 
(Figure 4.14) which, to my knowledge, has not been reported to date. Several studies have shown that 
CDCP1 plays a role in regulating cell-matrix adhesion of cancer cells [Brown et al., 2004b; Deryugina et 
al., 2009; Uekita et al., 2008a; Orchard-Webb et al., 2014]. Benes and colleagues demonstrated that the 
tyrosine phosphorylation of CDCP1 negatively controls adhesion of cancer cells to fibronectin-coated tissue 
culture plates [Benes et al., 2012]. Moreover, Bhatt and colleagues observed that overexpression of CDCP1 
led to changes in cell shape and thus detachment of MDA-468 breast cancer cells [Bhatt et al., 2005].   
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In IPF, activated myofibroblasts regulate connective tissue remodeling by producing and secreting excessive 
amounts of ECM components such as collagens and fibronectin. Recently, a study of Miyazawa et al. 
presented that absence of CDCP1 expression abolished ECM degradation through decreased secretion of 
MMP-9 protease in pancreatic cancer cells [Miyazawa et al., 2010]. Therefore, I investigated the impact of 
CDCP1 on ECM expression in human lung fibroblasts and found that knockdown of CDCP1 led to an 
increase in collagen III and collagen V protein expression in a TGFβ-dependent manner (Figure 4.15 A, B). 
The expression of collagen III is well-known to be highly enriched in IPF [Kenyon et al., 2003], whereas 
the expression of collagen V in IPF and its impact on ECM composition has not been described as 
intensively yet [Gelse et al., 2003; Erler and Weaver, 2009]. Therefore, future studies are necessary to 
uncover the special role of collagen V in this context.      
In sum, I showed that transmembrane glycoprotein CDCP1 negatively regulates TGFβ-mediated signaling 
events in primary human lung fibroblasts, since absence of CDCP1 enhances Smad3 phosphorylation, 
cellular adhesion, and total protein expression of αSMA, collagen III, and collagen V. Furthermore, I 
observed that TGFβ downregulates CDCP1 expression on the cell surface as well as total protein and mRNA 
levels and that this effect might be mediated via increased ubiquitin-independent degradation of CDCP1 in 
the proteasome. Therefore, my data suggest that a negative feedback loop between CDCP1 and TGFβ 
signaling exists by which CDCP1 negatively regulates TGFβ signaling in the context of fibroblasts to 
myofibroblasts transdifferentiation.  
Taken together, my thesis revealed that TGFβ alters the expression of the surface proteins PDGFRα and 
CDCP1 which in turn impacts their downstream signaling and finally cellular functions in lung fibroblasts 
strongly contributing to a profibrotic phenotype.  
This study thus highlights the importance of transmembrane proteins in fibroblasts biology, including 
processes essential to wound healing and their pathophysiological consequences in lung fibrosis.
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6 CONCLUSION AND FUTURE DIRECTIONS 
In my thesis I identified PDGFRα and CDCP1, two markers originally detected in a surface proteome 
analysis of phLFs in the presence/absence of TGFβ, to essentially take part in myofibroblast differentiation 
and strongly supporting the profibrotic phenotype, thereby interfering with TGFβ signaling. I investigated 
the consequence of their impaired expression by TGFβ on downstream signaling, and/or functional role in 
primary human lung fibroblasts.  
In particular, my data show that TGFβ alters not only the expression, but also downstream PDGFRα 
signaling which in turn leads to fibroblasts activation and thus enhanced ECM expression and secretion. 
Importantly, this effect occurs via a synergic cross-talk between PDGF and TGFβ signaling pathways. In 
the presence of TGFβ, Nintedanib was not able to block PDGF signaling which also resulted in increased 
ECM production and myofibroblasts differentiation. It is therefore important to test in future studies if 
patients with high TGFβ levels might respond to Nintedanib or instead need a special medical treatment 
additionally targeting TGFβ. In future, more mechanistic studies unraveling the cross-talk between PDGF 
and TGFβ signaling are necessary to identify signal transducers taking part in this process.  
In the second part of my thesis, my data indicate that a negative feedback loop between CDCP1 and TGFβ 
pathway exists by which CDCP1 contributes to fibroblasts activation and increased ECM expression. 
However, there is still limited information regarding CDCP1 signaling and its impact on fibroblast function. 
Therefore, further work is required to investigate the mechanism behind CDCP1 and TGFβ pathway 
interaction, in particular which signal transducers mediate downstream CDCP1 signaling and take part in 
cross-talk with TGFβ pathway. This would be addressed by performing phosphoproteomics of CDCP1-
depleted cells and identification of novel molecules and kinases of downstream CDCP1 signaling in primary 
human lung fibroblasts. Additionally, of importance is to investigate how TGFβ downregulates CDCP1 
expression on a transcription level. This would be addressed by using specific inhibitors or antagonists 
targeting CDCP1 transcription factors, in particular those regulated by TGFβ, such as GR, C/EBP beta, or 
PPAR gamma and would further provide an insight whether TGFβ regulates CDCP1 expression on different 
cellular levels in primary human lung fibroblasts.  
PDGF signaling is a well-known profibrotic signaling pathway in IPF, and therefore several tyrosine kinase 
inhibitors, including Nintedanib were designed to block the kinase activity of PDGF receptors in lung 
fibrosis. On the other hand, the clinical relevance of CDCP1 in IPF has not been investigated to date. 
Therefore, overexpression of CDCP1 in lung fibroblasts followed by immunoblot analysis of total protein 
levels of αSMA and ECM components in the presence or absence of TGFβ would be interesting to do. 
Finally, a clinical relevance of CDCP1 could be translated in in vivo situation by administrating bleomycin 
to CDCP1-homozygous or heterozygous mice with subsequent analysis whether CDCP1 depletion protects 
or promotes manifestation of lung fibrosis in those mice.  
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Although TGFβ is one of the most intensively studied profibrotic cytokine in IPF, it might be interesting to 
explore if other well-known cytokines taking part in IPF, such as PDGF, Wnt, or EGF ligands, interact with 
CDCP1 in phLFs. My data also confirmed and supported existing data that the surface proteome essentially 
contributes to a profibrotic phenotype of fibroblasts and is significantly regulated by cytokines. The surface 
proteome screen revealed the surface proteins Layilin, Glypican 1, FLRT3, and FERMT2, all of them not 
associated yet with fibroblasts or fibrosis. Thus, their role and importance in lung fibrosis have to be 
uncovered. Finally, future studies analyzing signaling and protein dynamics on the surface are important to 
identify specific fibroblasts surface markers involved in chronic lung diseases.
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